

UNIFORM GUIDANCE REPORTS AND SCHEDULES

Nationwide Children's Hospital, Inc. and Subsidiaries
Years Ended December 31, 2021 and 2020
With Reports of Independent Auditors

Ernst & Young LLP



Nationwide Children’s Hospital, Inc. and Subsidiaries

Uniform Guidance Reports and Schedules

Years Ended December 31, 2021 and 2020

Contents

Report of Independent Auditors.....	1
Consolidated Financial Statements	
Consolidated Balance Sheets	4
Consolidated Statements of Operations and Changes in Net Assets	6
Consolidated Statements of Cash Flows.....	8
Notes to Consolidated Financial Statements.....	9
Supplementary Information	
Schedule of Expenditures of Federal Awards.....	56
Notes to the Schedule of Expenditures of Federal Awards	72
Internal Control and Compliance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	73
Report of Independent Auditors on Compliance for the Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance.....	75
Schedule of Findings and Questioned Costs.....	79

Report of Independent Auditors

The Board of Directors
Nationwide Children's Hospital, Inc. and Subsidiaries

Opinion

We have audited the consolidated financial statements of Nationwide Children's Hospital, Inc. and Subsidiaries (the Corporation), which comprise the consolidated balance sheets as of December 31, 2021 and 2020, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements).

In our opinion, the accompanying financial statements present fairly, in all material respects, the consolidated financial position of the Corporation at December 31, 2021 and 2020, and the results of its operations, changes in its net assets, and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Corporation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Corporation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to April 26, 2022. The Schedule of Expenditures of Federal Awards, as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we also have issued our report dated April 26, 2022, on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Corporation's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

Ernst & Young LLP

April 26, 2022, except for our report on the
Schedule of Expenditures of Federal Awards
for which the date is September 30, 2022

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Balance Sheets

	December 31	
	2021	2020
	<i>(In Thousands)</i>	
Assets		
Current assets:		
Cash and cash equivalents	\$ 307,740	\$ 300,140
Restricted cash	151,153	46,564
Patient accounts receivable	367,423	251,996
Inventories	38,407	24,343
Pledges receivable <i>(Note 14)</i>	10,806	7,708
Premiums receivable	88,520	169,072
Other current assets	92,662	77,023
Total current assets	1,056,711	876,846
Assets limited as to use <i>(Note 5)</i> :		
Held by trustee	22,094	25,972
Board-designated:		
Capital improvement	78,167	71,675
Other	4,193,786	3,430,399
Donor restricted	414,893	377,843
Total assets limited as to use	4,708,940	3,905,889
Pledges receivable <i>(Note 14)</i>	12,768	15,660
Property and equipment, less allowance for depreciation <i>(Note 13)</i>	1,597,320	1,507,498
Other long-term assets	101,316	81,418
Total assets	<u>\$ 7,477,055</u>	<u>\$ 6,387,311</u>

	December 31	
	2021	2020
	<i>(In Thousands)</i>	
Liabilities and net assets		
Current liabilities:		
Accounts payable and accrued expenses	\$ 115,009	\$ 91,689
Compensation and related taxes	146,442	129,521
Current portion of long-term debt <i>(Note 8)</i>	81,107	80,963
Accrued claims expense	93,348	169,944
Other current liabilities	40,934	40,268
Total current liabilities	476,840	512,385
Long-term liabilities:		
Retirement benefits	13,901	26,823
Long-term debt <i>(Note 8)</i>	904,050	851,514
Professional liability	22,082	25,960
Interest rate swaps <i>(Note 10)</i>	32,723	46,758
Other long-term liabilities	89,085	78,706
	1,061,841	1,029,761
Total liabilities	1,538,681	1,542,146
Net assets:		
Without donor restrictions:		
Nationwide Children's Hospital, Inc.	5,385,171	4,462,596
Noncontrolling interest <i>(Note 1)</i>	143,088	—
Total net assets, without donor restrictions	5,528,259	4,462,596
With donor restrictions <i>(Note 18)</i>	410,115	382,569
Total net assets	5,938,374	4,845,165
Total liabilities and net assets	\$ 7,477,055	\$ 6,387,311

See accompanying notes.

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Operations and Changes in Net Assets

	Year Ended December 31	
	2021	2020
	<i>(In Thousands)</i>	
Unrestricted revenue, gains, and other support		
Patient service revenue <i>(Note 4)</i>	\$ 1,578,564	\$ 1,334,878
Premium revenue	1,579,777	1,249,158
Other revenue	276,429	261,006
Net assets released from restrictions	35,157	29,211
Total unrestricted revenue, gains, and other support	3,469,927	2,874,253
Expenses		
Salaries and benefits	1,310,044	1,205,909
Claims expense	942,577	699,811
Supplies	340,650	303,016
Purchased services	163,999	139,267
Interest	31,640	25,253
Depreciation and amortization	109,778	100,075
Other	256,472	220,386
Total operating expenses	3,155,160	2,693,717
Operating income	314,767	180,536
Investment return – net <i>(Note 5)</i>	575,452	393,287
Other nonoperating gains – net <i>(Note 1)</i>	22,230	9,097
Excess of revenue over expenses	912,449	582,920
Excess of revenue over expenses attributable to noncontrolling interest	—	—
Excess of revenue over expenses attributable to Nationwide Children's Hospital, Inc.	\$ 912,449	\$ 582,920

Continued on next page

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Operations and Changes in Net Assets (continued)

	Year Ended December 31, 2021			
	Attributable to			
	Attributable to NCH	Noncontrolling Interests	Total	2020
	<i>(In Thousands)</i>			
Net assets without donor restrictions				
Excess of revenue over expenses	\$ 912,449	\$ —	\$ 912,449	\$ 582,920
Change in pension obligation and assets	10,592	—	10,592	(364)
Net assets released from restrictions for the purchase of property and equipment	—	—	—	400
Issuance of noncontrolling interest	—	143,088	143,088	—
Transfers and other	(466)	—	(466)	(1,500)
Increase in net assets without donor restrictions	922,575	143,088	1,065,663	581,456
Net assets with donor restrictions				
Contributions	39,212	—	39,212	48,036
Net assets released from restrictions for the purchase of property and equipment	—	—	—	(400)
Investment return, net	27,483	—	27,483	20,925
Net assets released from restrictions	(35,157)	—	(35,157)	(29,211)
Transfers and other	(3,992)	—	(3,992)	1,038
Increase in net assets with donor restrictions	27,546	—	27,546	40,388
Increase in net assets	950,121	143,088	1,093,209	621,844
Net assets at beginning of year	4,845,165	—	4,845,165	4,223,321
Net assets at end of year	<u>\$ 5,795,286</u>	<u>\$ 143,088</u>	<u>\$ 5,938,374</u>	<u>\$ 4,845,165</u>

See accompanying notes.

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

	Year Ended December 31	
	2021	2020
	<i>(In Thousands)</i>	
Operating activities		
Increase in net assets	\$ 1,093,209	\$ 621,844
Adjustments to reconcile increase in net assets to cash provided by (used in) operating activities:		
Net change in unrealized gains on investments	(386,803)	(306,505)
Change in fair value of interest rate swaps	(14,035)	11,893
Change in pension obligation and assets	(10,592)	364
Depreciation and amortization	107,417	97,578
Net changes in assets limited as to use	(416,248)	(374,496)
Restricted contributions and investment income	(50,322)	(55,247)
Change in noncontrolling interest	(143,088)	—
(Increase) decrease in:		
Patient accounts receivable	(115,427)	55,804
Inventories	(14,064)	(12,453)
Premiums receivable	80,552	(130,260)
Other current assets	(15,639)	(18,054)
Pledges receivable	(206)	4,655
Other long-term assets	(19,898)	(10,451)
Increase (decrease) in:		
Accounts payable and accrued expenses	23,320	11,061
Compensation and related taxes	16,921	(13,196)
Other current liabilities	666	13,023
Accrued claims expense	(76,596)	98,216
Retirement benefits	(2,330)	(3,537)
Professional liability	(3,878)	(40)
Other long-term liabilities	10,379	(1,201)
Net cash provided by (used in) operating activities	<u>63,338</u>	<u>(11,002)</u>
Investing activities		
Purchase of property and equipment	(199,600)	(174,130)
Net cash used in investing activities	<u>(199,600)</u>	<u>(174,130)</u>
Financing activities		
Proceeds from issuance of long-term debt	75,000	148,925
Debt issuance costs	(6,641)	(1,559)
Repayment of long-term debt	(13,318)	(13,172)
Proceeds from issuance of noncontrolling interest	150,000	—
Noncontrolling interest issuance costs	(6,912)	—
Restricted contributions and investment income	50,322	55,247
Net cash provided by financing activities	<u>248,451</u>	<u>189,441</u>
Net increase in cash, cash equivalents and restricted cash	112,189	4,309
Cash, cash equivalents, and restricted cash at beginning of year	346,704	342,395
Cash, cash equivalents, and restricted cash at end of year	<u><u>\$ 458,893</u></u>	<u><u>\$ 346,704</u></u>

See accompanying notes.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

Years Ended December 31, 2021 and 2020

1. Organization and Significant Accounting Policies

Nationwide Children's Hospital, Inc. (Nationwide Children's) exclusively controls the activities of its subsidiaries in Central Ohio, including:

- **Nationwide Children's Hospital** (the Hospital) is a 696-bed not-for-profit tertiary care hospital, providing inpatient, outpatient, and emergency care services. Included within the bed count, the Hospital leases 145 neonatal intensive and special care nursery beds located at six other area hospitals. Subsidiaries of the Hospital include the following entities:
 - **Children's Radiological Institute** (CRI) is a not-for-profit professional practice plan owned by the Hospital, which provides radiological services at the Hospital.
 - **Nationwide Children's Hospital Homecare** (Homecare Services) is a not-for-profit home health company owned by the Hospital, which provides intermittent and private-duty nursing, skilled therapy, infusion therapy, durable medical equipment, hospice, and palliative care services.
 - **Pediatric Pathology Associates of Columbus** (PPAC) is a not-for-profit professional practice plan owned by the Hospital, which provides pathological services at the Hospital.
 - **Children's Surgical Associates** (CSA) is a not-for-profit professional practice plan owned by the Hospital, which provides surgical services at the Hospital.
 - **Pediatric Academic Association** (PAA) is a not-for-profit practice of which the Hospital owns 51%. The PAA is a group of approximately 500 medical, pediatric subspecialists, which provides such services at the Hospital. The remaining 49% ownership interest held by The Ohio State University Clinical Practice Plan was transferred to the faculty members of the Department of Pediatrics of The Ohio State University College of Medicine. The non-controlling interest was \$5,000 and \$(1,119,000) as of December 31, 2021 and 2020, respectively.
 - **Children's Anesthesia Associates, Inc.** (CAA) is a not-for-profit professional practice plan which provides anesthesiology services at the Hospital.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

- **Nationwide Children's Hospital Foundation** (Foundation) is a not-for-profit charitable foundation.
- **The Research Institute at Nationwide Children's Hospital** (Research Institute) is a not-for-profit pediatric medical research institute.
- **Center for Child and Family Advocacy at Nationwide Children's Hospital** (CCFA) is a not-for-profit organization that provides advocacy, education, counseling and other programmatic services to children and families suffering from child abuse and neglect. CCFA also is known by its operating name – The Center for Safety and Family Healing.
- **Children's Hospital and Physicians Healthcare Network** (d/b/a Partners for Kids) is a joint venture between the Hospital and community physicians. Partners for Kids is a not-for-profit formed to contract with insurers offering Medicaid or commercial managed care products for the provision of medical services. As a result of the Hospital's affiliation with certain physician groups, the Hospital has effective control of the Partners for Kids board and an economic interest in Partners for Kids.
- **Andelyn Biosciences, Inc. (Andelyn)** is a for-profit Phase 3 compliant Goods Manufacturing Practices (GMP) clinical manufacturing facility, producing materials for Phase 1, 2, and 3 gene therapy clinical studies for biotechnology and pharmaceutical industries. Andelyn is majority owned by Nationwide Children's and was formerly known as Pediatric Clinical Trials International, Inc. (PCTI). In March 2021, Nationwide Children's sold a minority equity ownership interest in Andelyn for \$150,000,000. In addition, Andelyn entered into a \$75,000,000 term loan with a private investor. Proceeds from these transactions will support construction of a \$200,000,000 manufacturing facility, operating cash flow requirements, and transaction costs. There was no change in control as a result of the transaction, and no gain recorded as a result. The agreement with the minority shareholder includes a purchase option, which provides the minority shareholder with the right to purchase shares of Andelyn from Nationwide Children's at fair value at any time following March 2025. Due to Nationwide Children's controlling equity interest, Andelyn will continue to be consolidated for financial reporting purposes. The non-controlling interest was \$143,088,000 as of December 31, 2021.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Basis of Presentation

The consolidated financial statements include the accounts of Nationwide Children's Hospital, Inc. and its subsidiaries, collectively referred to as Nationwide Children's or the Corporation. Significant interorganization accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Cash, Cash Equivalents, and Restricted Cash

Nationwide Children's defines cash as currency on hand and demand deposits with financial institutions. Cash equivalents are defined as short-term, highly liquid investments with remaining maturities of three months or less at the time of acquisition, excluding those held in assets limited as to use. The carrying amount of cash equivalents approximates fair value. Nationwide Children's had \$151,153,000 and \$46,564,000 of restricted cash deposited in escrow accounts related to Andelyn for construction of a new commercial manufacturing facility at December 31, 2021 and Partners for Kids for claims liability funding at December 31, 2021 and 2020, respectively.

Investments

Investments in equity securities and mutual funds with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheets. Investment return (including interest and dividends, realized gains and losses on the sale of investments, and changes in unrealized gains and losses on investments) is included in the excess of revenue over expenses, unless the income or loss is restricted by the donor or law.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Excess of Revenue Over Expenses

The consolidated statements of operations and changes in net assets include excess of revenue over expenses as the performance indicator. Changes in net assets, which are excluded from excess of revenue over expenses, consistent with industry practice, include contributions of long-lived assets (including assets acquired using contributions which by donor restriction, were to be used for the purposes of acquiring such assets), transfers and the change in pension obligations and assets.

Patient Accounts Receivable and Patient Service Revenue

Patient service revenue and patient accounts receivable are reported at the amount that reflects the consideration to which Nationwide Children's expects to be entitled in exchange for providing patient care.

Premium Revenue and Claims Expense

Premium Revenue

Premium revenue represents revenue derived under capitated arrangements between Partners for Kids and third parties, whereby Partners for Kids receives a per member per month (PMPM) amount for enrolled members. In return for these premiums, Partners for Kids has a performance obligation to provide essentially all health care services to enrolled participants for the duration of the contract. Premium revenue is recognized as Partners for Kids satisfies its performance obligations over time in the month in which the members are entitled to receive health care services. Under these capitated agreements, Partners for Kids assumes the economic risk of the members' health care services and related administrative costs. Costs for providing these services, including services provided by other health care providers, are included as claims expense in the consolidated financial statements. Partners for Kids may also receive retroactive adjustments to the health care premiums received based on the quality scores. The factors considered in this may change from year to year, but are typically based on Healthcare Effectiveness Data and Information Set (HEDIS) benchmarks related to behavioral health, certain chronic conditions and healthy children. In addition, the number of the members for whom Partners for Kids receives health care premiums may be retroactively adjusted due to enrollment changes not yet processed or reported. Partners for Kids generally estimates these retroactive adjustments using an expected value methodology, and amounts are only included to the extent that it is probable that a significant reversal of cumulative revenue will not occur once the uncertainty is resolved.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

As the performance obligation is recognized over time relate to contracts with a duration of one year or less, Partners for Kids has elected the practical expedient in Accounting Standards Codification (ASC) 606, *Revenue From Contracts With Customers*, which provides relief from the requirement to disclose the transaction price for remaining performance obligations at the end of each reporting period and the requirement to disclose when the company expects to recognize the related revenue.

During 2020, Partners for Kids expanded its operations into several counties in Ohio which contributed to growth in premium revenues, claims expenses, and related receivables and payables. In 2020, due to a delay and limitation in the ability of the managed care plan to automate data for a portion of the year, no funds were paid or received during 2020, and an estimate was recorded for the premium revenue and related receivable, as well as claims expense and related claims payable for the regions impacted. During 2021, a final settlement was determined and resulted in \$17 million favorable development recorded as a reduction to claims expense, which represented a change in estimate. Partners for Kids generates premium revenue through capitated contracts solely with Ohio Medicaid payors comprised of Medicaid programs: Covered Families and Children (CFC), Aged, Blind, and Disabled (ABD), and Adoption and Foster Kids (AFK).

For the years ended December 31, 2021 and 2020, capitation revenue is as follows:

	2021	2020
	<i>(In Thousands)</i>	
CFC	\$ 1,273,463	\$ 993,076
ABD	220,711	179,746
AFK	85,603	76,336
Total, December 31	<u>\$ 1,579,777</u>	<u>\$ 1,249,158</u>

Claims Expense and Accrued Claims Expense

Claims expense represents the cost of third-party health care services provided to members who are attributed to Partners for Kids for benefits covered within the capitated agreement. Claims expense does not include cost of services provided by Nationwide Children's. Claims expense is recognized in the period in which services are provided. This includes both claim payments processed in the period and also an estimate of the obligations for claims incurred but not reported. On an ongoing basis, Partners for Kids develops the estimated medical claims payable. This

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

process includes utilizing actuarial models when a sufficient amount of medical claims history is available from the third-party health care service providers. The actuarial models consider factors such as time from date of service to claim processing, seasonal variances in medical care consumption, health care professional contract rate changes, medical care utilization and other medical cost trends, membership volume and demographics. Partners for Kids reexamines previously recorded medical claims payable estimates based on actual claims submissions and other changes in facts and circumstances. As medical claims expense recorded in prior periods becomes more exact, Partners for Kids adjusts the amount of the estimate, and includes the change in medical claims expense in the period in which the change is identified. In each reporting period, total medical expense includes a change from the effects of more completely developed medical claims expense payable estimates associated with previously reported periods. While the Corporation believes its estimated incurred but not reported claims is adequate to cover future claims payments required, such estimates are based on its claims experience to date and various assumptions. Therefore, the actual liability could differ materially from the amount recorded.

Under the risk agreement, Partners for Kids is responsible for substantially all of the costs of all medical services provided to each member. Partners for Kids does not anticipate that revenues resulting from the risk arrangement will be insufficient to cover associated claims expenses from the period. If deemed necessary, Partners for Kids would recognize a premium deficiency liability. There is no premium deficiency liability recorded at December 31, 2021 and 2020.

Partners for Kids maintains stop-loss insurance coverage to limit exposure for certain catastrophic claims. The policy limit is \$2,000,000 per year per claim.

For the years ended December 31, 2021 and 2020, activity in the accrued claims expense is as follows:

	2021	2020
	<i>(In Thousands)</i>	
Balance, January 1	\$ 169,944	\$ 112,331
Incurred related to:		
Current period	851,799	687,770
Prior periods	(24,764)	30,330
Paid related to:		
Current period	(765,147)	(518,051)
Prior periods	(138,484)	(142,436)
Balance, December 31	<u>\$ 93,348</u>	<u>\$ 169,944</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Inventories

Inventories, consisting of drugs, medical and surgical supplies, are valued at the lower of cost, determined on a first-in, first-out basis, or market.

Property and Equipment

Property and equipment are stated at cost or at estimated fair value if acquired by gift. Depreciation of property and equipment is provided on the straight-line method at rates based on the estimated useful lives of the assets.

Bond Issuance Costs

Nationwide Children's records certain costs associated with the issuance of its bonds and reports these costs as a reduction in the related debt. The costs are amortized over the life of the bonds using a method that approximates the effective interest method.

Derivatives

Nationwide Children's uses interest rate swaps as part of its overall debt management policy. Nationwide Children's accounts for interest rate swaps in accordance with ASC 815, *Derivatives and Hedging*, which requires that all derivatives be carried at fair value in the consolidated balance sheets. The related changes in fair value are reported in the consolidated statements of operations and changes in net assets as a component of excess of revenue over expenses.

Fair Value

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value assessments are made at a specific point in time based on relevant market information about the financial instrument. See Note 6 for a description of the fair value hierarchy.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Community Benefits and Charity Care

Nationwide Children's provides programs and services to address the needs of those in the community with limited financial resources, generally at no or low cost to those being served. Additional services are provided to beneficiaries of governmental programs (principally those relating to the Medicare and Medicaid programs) at substantial discounts from established rates and are considered part of Nationwide Children's benefit to the community.

Assistance also is provided as needed to patients and their families for the submission of forms for insurance, financial counseling, and application to the Medicare and Medicaid programs for health service coverage. In addition, interpretive services are provided to those families who either cannot or have difficulty speaking English. The costs of providing these programs and services are included in expenses.

Consistent with Nationwide Children's mission, care is provided to patients regardless of their ability to pay. Patients who meet certain criteria for charity care are provided care without charge or at amounts less than established rates. Because collection of amounts determined to qualify as charity care is not pursued, such amounts are not reported as patient service revenue. Records are maintained to identify and monitor the level of charity care provided, including the amount of charges foregone for services and supplies furnished. The amount of charges foregone for services and supplies furnished under Nationwide Children's charity care policies for the years ended December 31 are as follows:

	<u>2021</u>	<u>2020</u>
Charges foregone, based on established rates	<u>\$ 45,726</u>	<u>\$ 62,330</u>
Management's estimate of costs incurred to provide charity care	<u>\$ 22,040</u>	<u>\$ 26,054</u>
Equivalent percentage of cost of charity care services to net patient service revenue, based on established rates	<u>48.2%</u>	<u>41.8%</u>

Estimates of costs incurred to provide charity care are based upon historical amounts derived from Medicaid cost reports.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Operating and Nonoperating Activities

Nationwide Children's principal activity is the provision of diversified health care services to the community. As such, activities related to the ongoing operations of Nationwide Children's are classified as revenue. Other revenue includes those generated from patient care related support services, research, certain donated revenue, royalty revenue from licensing agreements, and sundry revenue related to the operation of Nationwide Children's. Gains and losses not directly related to the ongoing operations of Nationwide Children's or that occur infrequently are reported as nonoperating gains and losses. Included in nonoperating gains and losses are unrestricted contributions, changes in fair value of interest rate swaps, interest rate swap termination costs, extinguishment of debt, revenue and costs associated with technology commercialization investments, and gains on the sale of property and equipment.

The following table sets forth other non-operating gains – net for the years ended December 31:

	2021	2020
	<i>(In Thousands)</i>	
Unrestricted contributions	\$ 7,086	\$ 16,638
Change in fair value of interest rate swaps	14,035	(11,893)
Technology investments	56	710
Distribution obligation	–	(602)
Swap termination gain (payment)	–	1,875
Other	1,053	2,369
Other nonoperating gains – net	<u>\$ 22,230</u>	<u>\$ 9,097</u>

Federal Income Taxes

Nationwide Children's is incorporated under the laws of the State of Ohio. Nationwide Children's and its subsidiaries, except Andelyn and NCH Realty, Inc., are tax-exempt organizations as defined under Section 501(c)(3) of the Internal Revenue Code. Income taxes on the for-profit subsidiaries, Andelyn and NCH Realty, Inc., are not significant.

Nationwide Children's records accruals for uncertain tax positions under ASC 740, *Income Taxes*. Nationwide Children's had no significant uncertain tax positions as of December 31, 2021 and 2020.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

COVID-19 Pandemic

On March 11, 2020, the World Health Organization declared the outbreak of Coronavirus Disease 2019 (COVID-19), a disease caused by a novel strain of coronavirus, a global pandemic. On March 9, 2020, the Governor of Ohio declared a state of emergency related to the COVID-19 outbreak, followed by, among other administrative or executive orders, an order of the Ohio Director of Health on March 17, 2020, canceling all nonessential surgeries and procedures in Ohio for the purpose of preserving personal protective equipment (PPE) and critical hospital capacity for the anticipated surge of COVID-19 patients. Such restrictions had a significant unfavorable impact on Nationwide Children's patient volumes and operations. The Governor of Ohio lifted the restrictions on nonessential surgeries and procedures effective May 1, 2020; however, volumes in some service areas continued to lag through December 31, 2020.

Federal and state governments enacted legislation and administrative actions to assist health care facilities in providing care to patients during the pandemic. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was enacted. Among other provisions, the CARES Act authorized relief funding to health care providers through the Public Health and Social Services Emergency Fund (Provider Relief Fund). During the year ended December 31, 2020, Nationwide Children's received distributions and payments from the Provider Relief Fund.

CARES Act Provider Relief and Other Funding

Distributions from the Provider Relief Fund are intended to reimburse health care providers for lost revenue and increased expenses related to the pandemic and are not subject to repayment; however, Nationwide Children's must attest to certain terms and conditions set forth by the legislation including, among other things, that distributions received were used for expenses and lost revenue resulting from COVID-19. Distributions provided by the CARES Act Provider Relief Fund are recognized as revenue once the applicable terms and conditions required to retain the distributions are met. Management performs ongoing analyses of the impact of the pandemic on Nationwide Children's operations and considers the compliance and reporting requirements set forth by the CARES Act, including subsequent issuance of all frequently asked questions and interpretive guidance issued by the U.S. Department of Health and Human Services (HHS), to determine the amount of government funds to recognize. The Provider Relief Fund Payment Terms and Conditions distributed by the HHS directs recipients to use distributed funds to prevent, prepare for, and respond to the COVID-19 pandemic and reimburses recipients only for health care expenses and lost revenues attributable to the pandemic. Guidance on the recognition and

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

reporting of government stimulus funds continues to evolve through the issuance of Post-Payment Notices of Reporting Requirements, each of which supplements and supersedes previously issued notices. During the year ended December 31, 2020, Nationwide Children's has received approximately \$81,584,000 of Provider Relief Fund payments, of which approximately \$79,385,000 was recognized as other revenue in the accompanying consolidated statement of operations and changes in net assets. The unrecognized amount of Provider Relief Fund payments is included in accounts payable and accrued expenses in the accompanying consolidated balance sheet as of December 31, 2020 and 2021. Issuance of new guidance and/or amended interpretations of existing guidance may result in changes to management's estimate of government stimulus revenue and, in certain cases, may result in derecognition of amounts previously recognized. No Provider Relief Fund payments were received during the year ended December 31, 2021.

The ongoing extent of the COVID-19 pandemic's impact on Nationwide Children's consolidated financial position, results of operations and cash flows will be driven by many factors, most of which are beyond Nationwide Children's control or ability to forecast. Such factors include, but are not limited to, the scope and duration of social distancing and stay-at-home orders, ongoing business closures and restrictions, increases in uninsured or underinsured patients as a result of high levels of unemployment, and supply chain disruptions, including shortages, delays, and significant price increases for medical supplies. Because of these factors and the changing scale and severity of the pandemic, its ultimate impact on Nationwide Children's operations is unknown.

2. Pending and Newly Adopted Accounting Guidance

In August 2018, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (ASU) 2018-15, *Intangibles – Goodwill and Other – Internal-Use Software, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract*. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. Nationwide Children's adopted this guidance on January 1, 2021 and there were no material impacts to the consolidated financial statements.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Pending and Newly Adopted Accounting Guidance (continued)

In January 2017, the FASB issued ASU 2017-04, *Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment*. This guidance eliminates Step 2 from the goodwill impairment test. Instead, an entity will test goodwill by comparing the fair value of a reporting unit with the carrying amount. This ASU is effective in the reporting period beginning January 1, 2022. Nationwide Children's does not expect this guidance to have a material impact on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, *Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes*. This guidance provides clarification on income taxes under ASC 740 by removing certain exceptions and improving consistent application of existing guidance. This ASU is effective in the reporting period beginning January 1, 2022. Nationwide Children's does not expect this guidance to have a material impact on its consolidated financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This guidance changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about contributed nonfinancial assets. This ASU is effective in the annual reporting period beginning January 1, 2022, with early adoption permitted. Nationwide Children's does not expect this guidance to have a material impact on its consolidated financial statements.

3. Third-Party Settlements

Estimated third-party settlements for various programs (Bureau of Children with Medical Handicaps, Medicare and Medicaid) reflect differences between interim reimbursement and reimbursement as determined by reports filed after the end of each year. In addition, such third-party settlements reflect, if applicable, any differences found to be owed to or by the Hospital after government agencies have audited these reports. The Hospital has received interim payments under Title V (Bureau of Children with Medical Handicaps) and Title XIX (Medicaid) programs but has not yet received final settlement for the years 2013 through 2021. Final settlement of amounts is subject to audit and verification by the appropriate governmental agency. The amounts reported in the consolidated financial statements represent the estimated settlements outstanding, which the Hospital's management believes will approximate final settlements.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

3. Third-Party Settlements (continued)

Revenue from the Medicaid program accounted for 20% and 17% of the Hospital's patient service revenue for the years ended December 31, 2021 and 2020, respectively. Laws and regulations governing the Medicaid program are complex and subject to interpretation. The Hospital believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicaid program. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

4. Patient Service Revenue

Nationwide Children's provides health care services through inpatient, outpatient, and ambulatory care facilities. Patient service revenue is reported at the amount that reflects the consideration to which Nationwide Children's expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, Nationwide Children's bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by Nationwide Children's. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Nationwide Children's believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation, based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the hospital receiving inpatient acute care services. Nationwide Children's measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided, and Nationwide Children's does not believe it is required to provide additional goods or services to the patient.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue (continued)

Because all of its performance obligations relate to contracts with a duration of less than one year, Nationwide Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Nationwide Children's uses a portfolio approach to account for categories of patient contracts as a collective group, rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and outpatient revenue. Based on the historical collection trends and other analysis, Nationwide Children's believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Nationwide Children's determines the transaction price based on standard charges for goods and services provided, reduced by explicit price concessions provided to third-party payors, discounts provided to uninsured patients in accordance with Nationwide Children's policy, and/or implicit price concessions provided to uninsured patients. Nationwide Children's determines its estimates of explicit price concessions based on contractual agreements, its discount policy, and historical experience. Nationwide Children's determines its estimate of implicit price concessions based on its historical collection experience with each class of patients.

Revenue from third-party payors is subject to retroactive adjustments due to audits, reviews, changes in program administration and rules, and outcome of litigation. These settlements are estimated based on the agreement with the payor and correspondence, which includes an assessment to ensure it is probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue (continued)

Agreements with third-party payors typically provide for payments at amounts less than established charges. The following is a summary of the payment arrangements with major third-party payors:

Commercial: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.

The Ohio Department of Medicaid administers a federally sponsored program, which provides additional reimbursement to hospitals that serve a disproportionate share of indigent patients (Care Assurance Program). The current program allocation formula generally is based on individual hospitals' components of indigent care in relation to statewide totals. Future funding of the Care Assurance Program is contingent on annual governmental approval, and the program's long-term existence is uncertain.

For the years ended December 31, 2021 and 2020, revenue recognized related to this program was recorded within patient service revenue in the consolidated statements of operations and changes in net assets, totaling \$45,002,000 and \$42,568,000, with offsetting HCAP assessments of \$5,731,000 and \$5,587,000, respectively. Nationwide Children's has recorded a liability of \$57,394,000 in other long-term liabilities in the consolidated balance sheets as of December 31, 2021 and 2020, related to this program. Of this amount, \$30,676,000 relates to 2015 and \$26,718,000 relates to 2014, based on information provided by the Ohio Department of Medicaid during 2015.

Self Pay: Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. Nationwide Children's also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. Nationwide Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue (continued)

to patient service revenue in the period of the change. For the years ended December 31, 2021 and 2020, the changes to the estimates of implicit price concessions for performance obligations satisfied in prior years were not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2021 and 2020 was \$352,000 and \$383,000, respectively.

Other: Payment agreements with certain governmental insurance carriers, government agencies, and non-government organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Patient service revenue by major payor source for the year ended December 31 is as follows:

	2021	2020
	<i>(In Thousands)</i>	
Commercial	\$ 1,216,948	\$ 1,045,487
Medicaid	308,760	233,410
Self-pay	14,172	15,692
Other	38,684	40,289
	<u>\$ 1,578,564</u>	<u>\$ 1,334,878</u>

Nationwide Children's has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component, due to Nationwide Children's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, Nationwide Children's does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Assets Limited as to Use

The composition of assets limited as to use at December 31 is set forth in the following table:

	December 31	
	2021	2020
	<i>(In Thousands)</i>	
Trustee funds:		
Cash equivalents	\$ 2,703	\$ 3,659
Fixed income:		
Mutual funds	9,574	9,567
Equities – mutual funds:		
Domestic large-cap indexed	4,341	5,440
Domestic mid-cap indexed	686	915
Domestic small-cap	1,169	1,501
International	2,634	3,526
Commodities fund	987	1,364
	22,094	25,972
Board-designated capital improvement:		
Cash equivalents	622	306
Fixed income:		
U.S Treasury bonds	2,596	—
U.S. Treasury notes	14,421	13,379
U.S. Government agencies	5,430	5,668
Corporate obligations	14,496	16,060
Foreign obligations	589	778
Mutual funds	6,624	6,288
Equities – mutual funds:		
Domestic large-cap indexed	14,169	11,815
Domestic mid-cap indexed	2,251	2,058
Domestic small-cap	1,780	1,739
International	7,541	7,013
Equity securities:		
Domestic small-cap	1,896	1,542
Commodities fund	3,688	2,865
Private equity	2,064	2,164
	78,167	71,675

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Assets Limited as to Use (continued)

	December 31	
	2021	2020
Board-designated other:		
Cash equivalents	\$ 201,484	\$ 255,963
Fixed income:		
U.S. Treasury bonds	48,732	27,433
U.S. Treasury notes	90,209	74,576
U.S. Government agencies	169,771	101,796
Corporate obligations	154,807	222,273
Foreign obligations	34,007	37,656
Mutual funds	353,495	297,299
Equities – mutual funds:		
Domestic large-cap indexed	1,405,165	1,017,506
Domestic mid-cap indexed	225,839	163,354
Domestic small-cap	166,536	137,332
International	730,307	647,856
Equity securities:		
Domestic small-cap	174,429	123,637
Commodities fund	177,321	128,151
Private equity and private credit	261,684	195,567
	<u>4,193,786</u>	<u>3,430,399</u>
Donor restricted:		
Cash equivalents	49,212	104,223
Fixed income:		
U.S. Treasury bonds	6,358	1,761
U.S. Treasury notes	20,964	16,151
U.S. Government agencies	18,674	11,347
Corporate obligations	26,162	27,899
Foreign obligations	3,276	3,079
Mutual funds	25,918	23,480
Equities – mutual funds:		
Domestic large-cap indexed	117,094	80,120
Domestic mid-cap indexed	18,482	13,317
Domestic small-cap	13,994	11,515
International	60,226	48,854
Equity securities:		
Domestic small-cap	14,099	10,111
Commodities fund	19,426	10,101
Private equity and private credit	20,100	15,059
Other	908	826
	<u>414,893</u>	<u>377,843</u>
Total assets limited as to use	<u>\$ 4,708,940</u>	<u>\$ 3,905,889</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Assets Limited as to Use (continued)

Nationwide Children's has committed capital yet to be called of approximately \$109,000,000 at December 31, 2021, to private equity and private credit funds over the next four to six years.

As of December 31, 2021 and 2020, assets limited as to use included an investment in a mutual fund equaling approximately 33% and 29%, respectively, of the consolidated investment balance. This passively managed fund is indexed to the S&P 500; therefore, management believes no concentration of credit risk exists with regard to this investment.

The composition of the investment return on board designated and funds held by trustee recognized in the consolidated statements of operations and changes in net assets is as follows for the year ended December 31:

	2021	2020
	<i>(In Thousands)</i>	
Investment return – net:		
Dividend and interest income	\$ 85,284	\$ 57,319
Realized gains on the sale of investments, net	119,738	43,176
Unrealized gains on investments, net	370,430	292,792
	<u>\$ 575,452</u>	<u>\$ 393,287</u>

The composition of the investment return on donor restricted assets limited as to use recognized in the consolidated statements of operations and changes in net assets is as follows for the year ended December 31:

	2021	2020
	<i>(In Thousands)</i>	
Investment return – net:		
Dividend and interest income	\$ 4,665	\$ 3,462
Realized gains on the sale of investments, net	6,445	3,750
Unrealized gains on investments, net	16,373	13,713
	<u>\$ 27,483</u>	<u>\$ 20,925</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements

Below is the fair value hierarchy that categorizes into three levels the inputs to valuation techniques that are used to measure fair value:

- Level 1 includes observable inputs that reflect quoted prices for identical assets or liabilities in active markets at the measurement date.
- Level 2 includes observable inputs for assets or liabilities other than quoted prices included in Level 1, and valuation techniques that use prices for similar assets and liabilities.
- Level 3 includes unobservable inputs that reflect the reporting entity's estimates of the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).

Management's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

Cash and cash equivalents principally are invested in money market funds. The money market funds are valued at their net asset value. Net asset value is equal to the fair value of each money market fund's investments and other assets, less liabilities, divided by the number of fund shares.

The money market funds are comprised of highly liquid investments with maturities of three months or less at date of acquisition and are classified as Level 1 instruments. Equity securities and mutual funds are valued at the closing price on the exchange where the security principally is traded, a market-based valuation technique. The instruments are classified as Level 1, because quoted prices in active markets are available. Nationwide Children's does not adjust quoted prices for such instruments.

U.S. Treasury bonds, U.S. Treasury notes, U.S. Government agencies, and corporate obligations are valued based upon a compilation of primarily observable market information or quoted prices that are not active. Foreign obligations are valued using vendor-evaluated prices. Because the evaluated prices for these fixed-income securities are based upon observable inputs, such as available trade information, spreads, bids and offers, broker feeds and reported trades, adjustments for corporate actions, and benchmark yields, instruments in these categories are classified as Level 2 securities. For interest rate swap liabilities, the Corporation uses a discounted cash flow analysis, incorporating interest rates and London Interbank Offered Rate (LIBOR) curves when assessing fair value, an income-based valuation technique. Such instruments generally are

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

classified as Level 2 securities. There are certain commodities funds, private equity and private credit investments that are accounted for using the equity method of accounting. These investments (certain commodities funds of \$94,083,000 and \$67,496,000 at December 31, 2021 and 2020, respectively, and private equity and private credit totaling \$283,848,000 and \$212,790,000 at December 31, 2021 and 2020, respectively) are not required to be marked to fair value on a recurring basis and, therefore, are not included in the accompanying tables. The carrying values of these investments are based on valuations provided by the administrators of the specific financial instruments. The underlying investments in these financial instruments may include marketable debt and equity securities, commodities, foreign currencies, derivatives, and private equity investments. The underlying investments are subject to various risks, including market, credit, liquidity, and foreign exchange risk. Nationwide Children's believes the carrying amount of these financial instruments in the consolidated balance sheets is a reasonable estimate of its ownership interest in the private equities. Because some of these financial instruments are not readily marketable, the estimated carrying value is subject to uncertainty and, therefore, may differ from the value that would have been used had a public market for such financial instruments existed. Nationwide Children's risk related to private equities is limited to its carrying value plus amounts committed to private equity as disclosed in Note 5. The private equity investments also have certain liquidity restrictions which generally range for the life of the fund. Once capital is contributed to a private equity fund, distribution timing is subject to the manager during the life of the fund.

The carrying amounts of the variable rate, long-term debt, as detailed in Note 8, approximate their fair values. The fair value of the fixed-rate, long-term debt is estimated using a discounted cash flow analysis, based on current incremental borrowing rates for similar types of borrowing arrangements. The fair value of the fixed rate, long-term debt at December 31, 2021 and 2020 is approximately \$730,975,000 (carrying value \$645,585,000) and \$749,846,000 (carrying value \$650,030,000), respectively. Nationwide Children's debt obligations are classified consistent with Level 2 of the fair value hierarchy.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

The following tables set forth Nationwide Children's assets and liabilities measured at fair value on a recurring basis as of December 31, aggregated by the level in the fair valued hierarchy within which those measurements are measured:

	2021			Total Fair
	Level 1	Level 2	Level 3	Value
	<i>(In Thousands)</i>			
Assets				
Cash and cash equivalents	\$ 254,021	\$ —	\$ —	\$ 254,021
Fixed income:				
U.S. Treasury bonds	—	57,686	—	57,686
U.S. Treasury notes	—	125,594	—	125,594
U.S. Government agencies	—	193,875	—	193,875
Corporate obligations	—	195,465	—	195,465
Foreign obligations	—	37,872	—	37,872
Mutual funds	392,971	2,640	—	395,611
Equities – mutual funds:				
Domestic large-cap indexed	1,540,769	—	—	1,540,769
Domestic mid-cap indexed	247,258	—	—	247,258
Domestic small-cap	183,479	—	—	183,479
International	800,708	—	—	800,708
Equities – securities:				
Domestic small cap	190,424	—	—	190,424
Commodities	105,850	—	—	105,850
Other	—	908	—	908
Total assets	<u>\$ 3,715,480</u>	<u>\$ 614,040</u>	<u>\$ —</u>	<u>\$ 4,329,520</u>
Liabilities				
Interest rate swaps	\$ —	\$ 32,723	\$ —	\$ 32,723
Total liabilities	<u>\$ —</u>	<u>\$ 32,723</u>	<u>\$ —</u>	<u>\$ 32,723</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

	2020			Total Fair Value
	Level 1	Level 2	Level 3	
	<i>(In Thousands)</i>			
Assets				
Cash and cash equivalents	\$ 364,151	\$ —	\$ —	\$ 364,151
Fixed income:				
U.S. Treasury bonds	—	29,194	—	29,194
U.S. Treasury notes	—	104,106	—	104,106
U.S. Government agencies	—	118,811	—	118,811
Corporate obligations	—	266,232	—	266,232
Foreign obligations	—	41,513	—	41,513
Mutual funds	333,345	3,289	—	336,634
Equities – mutual funds:				
Domestic large-cap indexed	1,114,881	—	—	1,114,881
Domestic mid-cap indexed	179,644	—	—	179,644
Domestic small-cap	152,087	—	—	152,087
International	707,249	—	—	707,249
Equities – securities:				
Domestic small cap	135,290	—	—	135,290
Commodities	74,985	—	—	74,985
Other	—	826	—	826
Total assets	<u>\$ 3,061,632</u>	<u>\$ 563,971</u>	<u>\$ —</u>	<u>\$ 3,625,603</u>
Liabilities				
Interest rate swaps	\$ —	\$ 46,758	\$ —	\$ 46,758
Total liabilities	<u>\$ —</u>	<u>\$ 46,758</u>	<u>\$ —</u>	<u>\$ 46,758</u>

The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are reasonable estimates of fair value due to the short-term nature of these financial instruments.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

7. Professional Liability Self-Insurance and Litigation

Nationwide Children's is subject to threatened legal actions, which arise in the normal course of its operating activities. Nationwide Children's risk management program regularly monitors its operations for potential claims. Various claimants have asserted professional and patient general liability claims for incidents that may give rise to litigation against Nationwide Children's. The claims are in various stages of evaluation and some ultimately may be brought to trial. There are also known incidents that have occurred through December 31, 2021, which may result in the assertion of additional claims, and there may be other claims related to unreported incidents arising from services provided to patients as of December 31, 2021.

Nationwide Children's has employed independent actuaries to estimate the ultimate cost, if any, of the settlement of such claims. Accrued professional liability losses have been discounted at an annual rate of 1.45% at December 31, 2021 and 2020, and, in management's opinion, provide adequate reserves for loss contingencies. As the actuarially determined accrual for professional and general liability is an estimate, the possibility exists that the estimate could be revised by a material amount in the near term.

To fund its self-insurance liability, Nationwide Children's maintains a trustee-held investment fund. Under the trust agreement, the trust assets can only be used for payment of professional and patient general liability losses, related expenses, and the cost of administering the trust.

On June 6, 2014 the United States Department of Treasury (DOT) concluded that the Hospital had violated certain provisions of the Code of Federal Regulations, which govern the use of the State and Local Government Series (SLGS) securities over a period from 2008 through 2012 in connection with advanced refunding of tax-exempt debt. As a consequence, the DOT suspended the Hospital from participating in the SLGS program for five years, with the possibility of a waiver with respect to certain purchases of SLGS securities. The Hospital disagreed with the DOT's decision, but elected not to contest the conclusion or suspension in court. On May 13, 2016, the United States Department of Justice (DOJ) informed the Hospital of its intention to investigate the Hospital's use of SLGS securities under the False Claims Act. The Hospital previously had discussions with the DOJ but has not had any discussions with the government since October 2018. At this time, the Hospital cannot predict the outcome of the DOJ investigation, including the potential materiality of any monetary consequences, and the Hospital cannot presently estimate the amount of contingent liability, if any, and therefore no liability amount has been recognized in the consolidated financial statements. The DOJ's investigation and related future claims, if any, if decided adversely to the interests of the Hospital, could be material to the Hospital.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt

Long-term debt consisted of the following at December 31:

	2021	2020
	<i>(In Thousands)</i>	
Hospital Improvement Revenue Bonds, Series 2020	\$ 148,925	\$ 148,925
Hospital Improvement Revenue and Improvement Bonds, Series 2019A	51,850	51,850
Hospital Improvement Revenue and Improvement Bonds, Series 2019B	92,150	92,150
Hospital Revenue Refunding and Improvement Bonds, Series 2017A	93,290	93,290
Hospital Revenue Refunding and Improvement Bonds, Variable Rate Demand, Series 2017B	45,070	45,345
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2016A	5,585	6,865
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2016B	24,310	26,270
Hospital Revenue Refunding Bonds, Series 2016C	123,525	126,325
Hospital Improvement Revenue Bonds, Series 2015A	75,000	75,000
Hospital Improvement Revenue Bonds, Variable Rate Demand, Series 2015B	25,000	25,000
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2014A	7,290	9,030
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2014B	45,580	45,580
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2013A	30,835	32,610
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2013B	12,945	14,335
Hospital Improvement Revenue Bonds, Series 2012A	60,845	62,490
Hospital Improvement Revenue Bonds, Variable Rate Demand, Series 2008B	42,645	42,975
Andelyn term loan	75,000	—
Finance lease obligations	1,340	1,462
Total long-term debt, including current portion	961,185	899,502
Bond discounts, premium and issuance cost – net	23,972	32,975
Less current portion of bonds and finance lease obligations	(81,107)	(80,963)
	<u>\$ 904,050</u>	<u>\$ 851,514</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In October 2020, the County of Franklin, Ohio (the County) issued \$148,925,000 of Hospital Improvement Revenue Bonds (the 2020 Bonds). The 2020 Bonds consisted of \$148,925,000 term bonds due in 2050. The term bonds are taxable and bear annual interest at 2.88%. The 2020 Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities. In September 2020, Nationwide Children's entered into a taxable interest rate swap agreement with the intent of hedging the interest rate risk related to the 2020 Bonds. The notional amount of this agreement was \$60,000,000. The agreement was terminated in November 2020, and the fair value of the swap resulted in a termination payment to Nationwide Children's of approximately \$1,875,000, which is included in other non-operating gains – net for the year ended December 31, 2020.

In November 2019, the County issued \$51,850,000 of Hospital Improvement Revenue Bonds (the 2019A Bonds). The 2019A Bonds consisted of \$51,850,000 term bonds due in 2048. The term bonds bear annual interest at 5%. The 2019A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In November 2019, the County issued \$92,150,000 of Hospital Improvement Revenue Bonds (the 2019B Bonds). The 2019B Bonds consisted of \$92,150,000 term bonds due in 2050. The term bonds are taxable and bear annual interest at 3.38%. The 2019B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and a portion of the proceeds were used to fund the interest rate swap termination payment described below.

In November 2017, the County issued \$93,290,000 of Hospital Revenue Refunding and Improvement Bonds (the 2017A Bonds). The 2017A Bonds consisted of \$68,825,000 serial bonds, maturing in varying amounts from 2028 through 2039; \$12,935,000 of term bonds due in 2044; and \$11,530,000 of term bonds due in 2047. The serial bonds bear annual interest at rates ranging from 3.125% to 5% as of December 31, 2021 and 2020, respectively. The term bonds due in 2044 and 2047 bear annual interest at 4%. The 2017A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and for the current refunding of a portion of the 2008D bonds.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In November 2017, the County issued \$46,150,000 of Hospital Revenue Refunding and Improvement Bonds (the 2017B Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments beginning on November 1, 2018, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. The bonds bear annual interest at an adjustable rate, which was 0.001% and 0.09% at December 31, 2021 and 2020, respectively. The 2017B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and for the current refunding of a portion of the 2008D bonds.

In April 2016, the County issued \$47,670,000 of Hospital Revenue Refunding Bonds (the 2016A and 2016B Bonds). These bonds were purchased by a bank to which Nationwide Children's makes varying principal payments beginning on May 1, 2017 and ending on May 1, 2026. On May 1, 2026 (expiration date of the bank purchase agreement), \$16,125,000 of unpaid principal will remain outstanding. The bonds bear annual interest at an adjustable rate, which was 0.57% and 0.06% annually as of December 31, 2021 and 2020, respectively, payable monthly. The 2016A and 2016B Bonds were issued for the purpose of current refunding of the 2008C and 2008F Bonds.

In November 2016, the County issued \$129,290,000 of Hospital Revenue Refunding Bonds (the 2016C Bonds). The 2016C Bonds consisted of \$55,960,000 and \$58,760,000 serial bonds as of December 31, 2021 and 2020, respectively, maturing in increasing amounts from 2019 through 2036; \$9,140,000 term bonds due in 2031, and \$58,425,000 term bonds due in 2040. The serial bonds bear interest at annual rates ranging from 3.25% to 5% as of December 31, 2021 and 2020, respectively. The term bonds due in 2031 and 2040 bear annual interest at 5% and 4%, respectively. The 2016C Bonds were issued for the purpose of advance refunding portions of the 2008A and 2009 Bonds.

In May 2015, the County issued \$75,000,000 of Hospital Improvement Revenue Bonds (the 2015A Bonds). The bonds consisted of \$75,000,000 of term bonds due in 2045. The term bonds bear annual interest at 4%. The 2015A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2015, the County issued \$25,000,000 of Hospital Improvement Revenue Bonds (the 2015B Bonds). The bonds mature in 2045, but are subject to redemption prior to maturity under various scenarios. The 2015B bonds bear annual interest at a variable rate, which was 0.001% and 0.05% as of December 31, 2021 and 2020, respectively, payable monthly. Since the 2015B Bonds are

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

remarketed weekly, they are classified within current portion of long-term debt in the consolidated balance sheets. They were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2015, the County issued \$17,225,000 of Hospital Revenue Refunding Bonds (the 2014A Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning on May 1, 2016, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. The bonds bear annual interest at an adjustable rate, which was 0.001% and 0.09% as of December 31, 2021 and 2020, respectively, payable monthly.

In May 2015, the County issued \$45,580,000 of Hospital Revenue Refunding Bonds (the 2014B Bonds). These bonds were purchased by a bank and no principal payments are due during the term of the agreement. On May 1, 2025 (expiration date of the bank purchase agreement), \$45,580,000 of unpaid principal will remain outstanding. The bonds bear annual interest at an adjustable rate, which was 0.59% and 0.09% as of December 31, 2021 and 2020, respectively, payable monthly.

In June 2013, the County issued \$44,155,000 of Hospital Revenue Refunding Bonds (the 2013A Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning November 1, 2013, and ending November 1, 2019, at which time the bank purchase agreement was terminated. The 2013A Bonds bear interest at an annual adjustable rate, which was 0.001% and 0.09% as of December 31, 2021 and 2020, respectively, payable monthly.

In June 2013, the County issued \$22,830,000 of Hospital Revenue Refunding Bonds (the 2013B Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning on May 1, 2014, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. The 2013B Bonds bear annual interest at an adjustable rate, which was 0.001% and 0.09% as of December 31, 2021 and 2020, respectively, payable monthly.

In May 2012, the County issued \$75,000,000 of Hospital Improvement Revenue Bonds (the 2012A Bonds). The 2012A Bonds consisted of \$10,845,000 and \$12,490,000 serial bonds as of December 31, 2021 and 2020, respectively, maturing in varying amounts through 2027, and \$50,000,000 term bonds due in 2042. The serial bonds bear annual interest at rates ranging from 3% to 5% as of December 31, 2021 and 2020, respectively. The term bonds bear annual interest at 5%. The 2012A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In May 2008, the County issued \$45,000,000 of Hospital Improvement Revenue Bonds (the 2008B Bonds). The bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments, beginning on November 1, 2013, and ending on November 1, 2040. The 2008B Bonds bear annual interest at a variable rate, which was 0.001% and 0.50% as of December 31, 2021 and 2020, respectively, payable monthly. Since the 2008B Bonds are remarketed weekly, they are classified within the current portion of long-term debt in the consolidated balance sheets. The 2008B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

The owners of the 2017B, 2014A, 2013A, and 2013B Bonds have the option to demand payment of their outstanding bonds. On November 1, 2019, Nationwide Children's entered into Stand-by Bond Purchase Agreements (the Agreements) for each of these bond issues with a bank which require the remarketing agent to utilize its best efforts to remarket any such bonds that may be tendered for payment. In the event any such bonds cannot be remarketed, the Agreements provide that the bank will provide payment for the bonds tendered. Should certain events occur, the amounts due to the bank will be converted to a term loan, for which Nationwide Children's has an obligation to make payment over three years, in quarterly payments, plus any accrued interest.

The owners of the 2015B and 2008B Bonds have the option to demand payment of their outstanding bonds. Should the remarketing agent be unsuccessful in remarketing these bonds, Nationwide Children's is providing its own liquidity as the repayment source to the bondholders.

Interest on the 2019A Bonds, 2019B Bonds, 2017A Bonds, 2016C Bonds, 2015A Bonds, and 2012A Bonds is payable semi-annually on May 1 and November 1 of each year.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

On March 18, 2021 (the Effective Date), Andelyn entered into a Credit Agreement with an unrelated third party and its affiliates (the Lenders). Pursuant to the Credit Agreement, Andelyn entered into a senior secured Term Loan for \$75,000,000 which matures in September 2027. The Term Loan bears interest equal to the greater of the prime rate, Federal Funds Effective Rate or the Eurodollar Rate plus 1.00% plus an applicable margin. As of December 31, 2021, the interest rate in effect was 9.00%. The Term Loan is secured by substantially all of the assets of Andelyn. The Credit Agreement contains customer financial and nonfinancial covenants that Andelyn must comply with until all loans and other obligations are paid in full. No financial covenants were in place as of December 31, 2021. Interest expense, net of capitalized interest, incurred on the Term Loan amounted to \$4,100,000 for the year ended December 31, 2021 and is included in interest expense in the consolidated statement of operations and changes in net assets. The Term Loan requires no periodic principal payments and is due in full at maturity. As of December 31, 2021, there are no payments due under the Term Loan for the succeeding five years ended December 31.

Nationwide Children's made interest payments on long-term debt of \$29,783,000 and \$22,590,000 during 2021 and 2020, respectively.

In connection with the issuance of the Bonds, the County acquired title to substantially all of the Hospital's facilities and real property. The facilities and real property are, in turn, being leased to the Hospital through 2052, the latest mandatory retirement date of the Bonds, with payment terms equal to the debt service requirements of the Bonds. A provision of the lease grants an option to the Hospital to purchase the facilities for a nominal sum after provision has been made to retire the Bonds. The Hospital's facilities and real property are accounted for as a finance lease in the consolidated balance sheets.

Provisions of the Bonds require Nationwide Children's to, among other things, comply with certain financial ratios, restrict additional encumbrances, restrict the sale or acquisition of certain assets, or merge with another entity. As of December 31, 2021 and 2020, Nationwide Children's was in compliance with its debt covenants.

Aggregate scheduled maturities of long-term debt in each of the following five years are: 2022 – \$13,675,000; 2023 – \$14,180,000; 2024 – \$14,710,000; 2025 – \$15,280,000 and 2026 – \$16,065,000.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

9. Leases

Nationwide Children's has operating and finance leases for real estate, personal property and equipment. Nationwide Children's determines if an arrangement is a lease at the inception of a contract. Operating lease right-of-use assets are included in other long-term assets and operating lease liabilities are included in other current and long-term liabilities in the consolidated balance sheets. Nationwide Children's had right-of-use assets and lease liabilities for operating leases totaling approximately \$20,938,000 and \$22,118,000, respectively, at December 31, 2021. Nationwide Children's had right-of-use assets and lease liabilities for operating leases totaling approximately \$24,915,000 and \$26,326,000, respectively, at December 31, 2020. Finance lease right-of-use assets are included in property and equipment and the related lease liabilities are included in current portion of long-term debt and long-term debt in the consolidated balance sheets. Nationwide Children's had right-of-use assets and lease liabilities for finance leases totaling approximately \$1,377,000 and \$1,340,000, respectively, at December 31, 2021. Nationwide Children's had right-of-use assets and lease liabilities for finance leases totaling approximately \$1,337,000 and \$1,462,000, respectively, at December 31, 2020. Leases with an initial term of twelve months or less are not recorded in the consolidated balance sheets. Nationwide Children's has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component.

Right-of-use assets represent Nationwide Children's right to use an underlying asset during the lease term and lease liabilities represent Nationwide Children's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date based on the net present value of fixed lease payments over the lease term. Nationwide Children's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of the operating leases do not provide an implicit rate, Nationwide Children's uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Nationwide Children's considers recent debt issuances, as well as publicly available data for instruments with similar characteristics, when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

9. Leases (continued)

Operating expenses for the leasing activity of Nationwide Children's as lessee for the year ended December 31 are as follows:

	Classification	2021	2020
		<i>(In Thousands)</i>	
Operating lease expense	Facilities expense	\$ 6,575	\$ 7,304
Financing lease interest	Interest expense	70	56
Financing lease amortization	Depreciation and amortization	135	143
Total lease cost		<u>\$ 6,780</u>	<u>\$ 7,503</u>

Supplemental cash flow information for the year ended December 31 is as follows:

	2021	2020
	<i>(In Thousands)</i>	
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases	\$ 6,766	\$ 7,469
Operating cash flows from finance leases	70	56
Financing cash flows from finance leases	123	134
Total	<u>\$ 6,959</u>	<u>\$ 7,659</u>

The aggregate future lease payments for operating and finance leases as of December 31, 2021 are as follows:

	Operating	Finance
	<i>(In Thousands)</i>	
2022	\$ 5,814	\$ 196
2023	4,694	199
2024	3,958	201
2025	2,871	214
2026	2,555	218
Thereafter	5,640	596
Total lease payments	25,532	1,624
Less: imputed interest	(3,414)	(284)
Present value of lease liabilities	<u>\$ 22,118</u>	<u>\$ 1,340</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

9. Leases (continued)

Average lease terms and discount rates as of December 31 are as follows:

	2021	2020
Weighted-average remaining lease term (years):		
Operating leases	5.9	6.3
Finance leases	7.7	8.7
Weighted-average discount rate:		
Operating leases	4.9%	5.0%
Finance leases	5.0%	5.0%

10. Derivatives

Nationwide Children's has entered into various interest rate swap agreements with the intent of mitigating Nationwide Children's cash flow risk relating to changes in the variable interest rates of its bonds as listed within the following table. Under the swap agreements, Nationwide Children's pays interest at fixed rates (see table below) and receives interest at variable rates. Net interest paid or received under the swap agreements is included in interest expense. The following schedule outlines the terms and fair values of the interest rate swap agreements.

	Series 2008B	Series 2017B	Series 2013A	Series 2013B	Series 2014A	Series 2014B	Series 2016A	Series 2016B
<i>(In Thousands)</i>								
Notional amount at								
December 31, 2021	\$ 42,645	\$ 44,885	\$ 4,765	\$ 12,865	\$ 7,290	\$ 45,580	\$ 5,565	\$ 24,195
Effective date	5-1-08	11-1-10	11-1-06	9-23-05	5-1-15	5-1-15	12-12-02	9-1-05
Termination date	11-1-40	11-1-33	11-1-25	5-1-29	5-1-25	5-1-35	11-1-25	5-1-31
Fixed annual rate	4.13%	3.22%	3.66%	3.19%	1.78%	2.06%	3.28%	3.57%
Fair value at								
December 31, 2019	(16,406)	(9,159)	(593)	(1,499)	(239)	(4,462)	(608)	(3,928)
Unrealized loss	(3,795)	(2,409)	(4)	(315)	(128)	(2,912)	(23)	(734)
Credit risk adjustment	720	185	(1)	4	—	149	(1)	30
Fair value at								
December 31, 2020	(19,481)	(11,383)	(598)	(1,810)	(367)	(7,225)	(632)	(4,632)
Unrealized loss	4,856	2,912	260	668	194	2,421	276	1,457
Credit risk adjustment	(461)	(102)	(1)	(6)	(1)	(86)	(1)	(22)
Fair value at								
December 31, 2021	\$ (15,086)	\$ (8,573)	\$ (339)	\$ (1,148)	\$ (174)	\$ (4,890)	\$ (357)	\$ (3,197)

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Derivatives (continued)

In January 2009, Nationwide Children's entered into a speculative interest rate swap. The initial notional amount of this interest rate swap agreement was \$45,000,000, and the effective date of the transaction was January 1, 2011. Nationwide Children's pays interest based on 100% of the monthly Securities Industry and Financial Markets Association (SIFMA) Municipal Swap Index, and receives interest based on 100.89% of the 3-month LIBOR. The notional amount was \$42,645,000 and \$42,975,000 at December 31, 2021 and 2020, respectively. The fair value was \$1,127,000 and \$1,249,000 at December 31, 2021 and 2020, respectively, and the asset is netted against the interest rate swap liability in the consolidated balance sheets.

In December 2018, Nationwide Children's entered into a speculative interest rate swap agreement. The initial and current notional amount of this interest rate swap agreement was \$100,000,000, and the effective date of the transaction was January 1, 2020. Nationwide Children's pays interest based on 67% of 1-month LIBOR, and receives interest based on 55.33% of 10-year LIBOR. The fair value was \$1,525,000 and \$3,336,000 at December 31, 2021 and 2020, respectively, and the asset is netted against the interest rate swap liability in the consolidated balance sheets.

In July 2019, Nationwide Children's entered into an interest rate swap agreement with the intent of hedging Nationwide Children's interest rate risk related to a prospective bond refunding planned for May 2022. The notional amount of this interest rate swap agreement was \$61,305,000, and the effective date is May 1, 2022. Nationwide Children's will pay interest at a fixed rate of 1.78% and will receive interest based on the SIFMA Municipal Swap Index. The fair value was \$(1,611,000) and \$(5,215,000) at December 31, 2021 and 2020, respectively, and the liability is included in the interest rate swap liability in the consolidated balance sheets.

Nationwide Children's has recorded the fair value of the interest rate swap agreements of \$(32,723,000) and \$(46,758,000) as a long-term liability in the consolidated balance sheets as of December 31, 2021 and 2020, respectively. The change in fair market value of the interest rate swap agreements of \$14,035,000 and \$(11,893,000) in 2021 and 2020, respectively, is included in other nonoperating gains – net.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Derivatives (continued)

The following table presents the fair value of derivative instruments, location of the related instruments in the consolidated balance sheets and the related notional amounts of the derivative instruments as of December 31, 2021 and 2020:

	Derivative Liabilities			
	Balance Sheet Location	Fair Value	Notional Amount	
	(In Thousands)			
Derivatives not designated as hedging instruments:				
	Interest rate swaps	\$ 32,723	\$	391,740
	Interest rate swaps	\$ 46,758	\$	400,075

Nationwide Children's made net payments on interest rate swaps of approximately \$5,917,000 and \$5,311,000 during 2021 and 2020, respectively, which are recorded within interest expense, net of the change in accruals for these payments.

11. Defined Benefit Plan

Nationwide Children's has a defined benefit pension plan (the Plan) for employees who meet certain requirements as to age and length of service. Nationwide Children's funding policy is to make at least the minimum annual contributions required by applicable regulations.

The Plan was curtailed effective December 31, 1996, with respect to: (1) any employee under the age of 45, (2) any employee over the age of 45 who was not fully vested in his or her accrued benefit under the Plan, and (3) any other participant who elected to cease his or her participation in the Plan (affected participants). At that time, the accrued benefits of each affected participant became fully vested and non-forfeitable.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

The following tables set forth the change in benefit obligation, change in plan assets, funded status, and components of net periodic benefit cost of the Plan:

	December 31	
	2021	2020
	<i>(In Thousands)</i>	
Change in benefit obligation		
Benefit obligation, beginning of the year	\$ 91,730	\$ 88,054
Service cost	340	560
Interest cost	1,724	2,427
Actuarial losses	(3,184)	7,004
Benefits paid	(5,612)	(6,315)
Benefit obligation, end of year	84,998	91,730
Change in plan assets		
Fair value of plan assets, beginning of the year	77,450	72,546
Actual return on plan assets	10,383	9,718
Employer contributions	1,060	1,501
Benefits paid	(5,612)	(6,315)
Fair value of plan assets, end of the year	83,281	77,450
Funded (deficit)	\$ (1,717)	\$ (14,280)
	Year Ended December 31	
	2021	2020
	<i>(In Thousands)</i>	
Components of net periodic pension cost		
Service cost	\$ 340	\$ 560
Interest cost	1,724	2,427
Expected return on plan assets	(4,764)	(4,649)
Amortization of net loss	1,793	1,571
Net periodic pension (credit), cost	\$ (907)	\$ (91)

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

Weighted average assumptions used to determine benefit obligations as of December 31 are as follows:

	2021	2020
Discount rate	2.4%	1.94%
	Pri-2012 with fully generational projection using scale MP-2021	Pri-2012 with fully generational projection using scale MP-2020
Mortality		

Weighted average assumptions used to determine net periodic pension cost for the years ended December 31 are as follows:

	2021	2020
Discount rate	1.94%	2.84%
Expected return on plan assets	7.00%	7.00%
	2021 PPA optional combined mortality	2020 PPA optional combined mortality
Mortality		

Included as a reduction in net assets without donor restrictions are actuarial losses of \$22,437,000 and \$33,029,000 at December 31, 2021 and 2020, respectively, which will be recognized in net periodic pension cost in future periods.

The accumulated benefit obligation of the Plan at December 31, 2021 and 2020 was \$84,998,000 and \$91,730,000, respectively.

Expected benefit payments for the next ten years are: 2022 – \$6,234,000; 2023 – \$6,168,000; 2024 – \$6,070,000; 2025 – \$5,972,000; 2026 – \$5,861,000 and 2027 through 2031 – \$27,009,000.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

The allocation of Plan assets by major category as a percentage of total Plan assets is set forth in the following table:

	December 31			
	2021		2020	
	Actual	Target	Actual	Target
Domestic equities	56%	43%	53%	43%
International equities	9	7	10	7
Fixed income and cash equivalents	35	50	37	50
	100%	100%	100%	100%

The target asset allocations are designed to match expected returns with the time horizon for the liabilities of the Plan, and are periodically reviewed and approved by the Finance Committee of the Board of Directors. The use of derivatives is currently not permitted by the Plan's investment policy. The expected long-term rate of return assumption is based upon historical returns and management's belief that future returns will approximate historical returns over a long-term time horizon.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

The fair value of plan assets at December 31 is as follows:

2021				
	Level 1	Level 2	Level 3	Total Fair Value
	<i>(In Thousands)</i>			
Cash and cash equivalents	\$ 5,420	\$ —	\$ —	\$ 5,420
Fixed income:				
U.S. Treasury bonds and notes	—	10,536	—	10,536
U.S. Government agencies	—	1,325	—	1,325
Corporate obligations	—	11,539	—	11,539
Equities – mutual funds:				
Domestic large-cap indexed	33,558	—	—	33,558
Domestic mid-cap indexed	5,589	—	—	5,589
Domestic small-cap indexed	7,704	—	—	7,704
International	7,610	—	—	7,610
Total	\$ 59,881	\$ 23,400	\$ —	\$ 83,281
2020				
	Level 1	Level 2	Level 3	Total Fair Value
	<i>(In Thousands)</i>			
Cash and cash equivalents	\$ 4,441	\$ —	\$ —	\$ 4,441
Fixed income:				
U.S. Treasury bonds and notes	—	9,506	—	9,506
U.S. Government agencies	—	2,641	—	2,641
Corporate obligations	—	12,101	—	12,101
Equities – mutual funds:				
Domestic large-cap indexed	28,406	—	—	28,406
Domestic mid-cap indexed	4,951	—	—	4,951
Domestic small-cap indexed	7,691	—	—	7,691
International	7,713	—	—	7,713
Total	\$ 53,202	\$ 24,248	\$ —	\$ 77,450

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

Fair value methodologies for Level 1, 2 and 3 are consistent with the inputs described in Note 6.

The Hospital will not make a contribution to the Plan during 2022. The Hospital estimates that it will amortize \$1,385,000 of the net actuarial losses from net assets without donor restrictions into net periodic pension cost during 2022.

12. Defined Contribution Plans

Effective January 1, 1997, the Matching Plan was amended and renamed as the Nationwide Children's Hospital Employee Defined Contribution Plan (Defined Contribution Plan). The Defined Contribution Plan includes both an employee matching contribution and an additional employer defined contribution and contains provisions specifically permitting affected participants to transfer distributions received from the revised pension plan. The employer defined contribution is based upon certain percentages of employees' wages, which are determined based upon length of service and income levels.

Nationwide Children's provides a 403(b) matching contribution plan for essentially all employees who have met specified service requirements. Under the plan, Nationwide Children's matches 50% of the first 3% of salaries contributed by each participant, up to a maximum of 1.5% of the participant's salary.

Nationwide Children's incurred expenses related to these plans totaled \$55,220,000 and \$48,442,000 during 2021 and 2020, respectively.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

13. Property and Equipment

Details of property and equipment are summarized as follows as of December 31:

	2021	2020
	<i>(In Thousands)</i>	
Land and land improvements	\$ 95,690	\$ 92,447
Buildings and improvements	1,686,697	1,646,173
Equipment	459,822	406,849
Construction-in-progress	182,338	85,802
	<u>2,424,547</u>	<u>2,231,271</u>
Allowances for depreciation	(827,227)	(723,773)
	<u><u>\$ 1,597,320</u></u>	<u><u>\$ 1,507,498</u></u>

The ranges of useful lives associated with the following categories of property and equipment are as follows: land improvements – 8–15 years; buildings and improvements – 10–30 years; equipment – 5–20 years.

Outstanding commitments for the purchase of property and equipment were approximately \$37,141,000 and \$27,440,000 at December 31, 2021 and 2020, respectively. Nationwide Children's expects to pay outstanding commitments at December 31, 2021 and during 2022, using funds from operations and fundraising contributions

14. Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of estimated future cash flows. The annual discounts applied to these amounts are computed by using an applicable annual interest rate to the year in which the promise is received, which is up to 4.5%.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

14. Pledges Receivable (continued)

The following is a summary of pledges receivable and the anticipated schedule of their receipt, for the years ended December 31:

	2021	2020
	<i>(In Thousands)</i>	
Gross unconditional pledges receivable	\$ 26,635	\$ 26,496
Less:		
Allowance for doubtful pledges	(796)	(884)
Unamortized discount	(2,265)	(2,244)
Net unconditional pledges receivable	<u>\$ 23,574</u>	<u>\$ 23,368</u>
Amounts due in:		
Less than one year	\$ 12,616	\$ 9,341
One to five years	12,203	16,356
Greater than five years	1,816	799
Total	<u>\$ 26,635</u>	<u>\$ 26,496</u>

15. Functional Expenses

Nationwide Children's provides a complete range of preventive, diagnostic, therapeutic and rehabilitative pediatric health services to residents within a 34-county area encompassing central, southern and southeastern Ohio. The tables below present expenses related to providing these services by both nature and function for the years ended December 31:

	2021					
	Healthcare Services	Management and General	Foundation	Research	Education	Total
	<i>(In Thousands)</i>					
Salaries and benefits	\$ 829,826	\$ 319,062	\$ 4,683	\$ 122,334	\$ 34,139	\$1,310,044
Claims expense	942,577	—	—	—	—	942,577
Supplies	292,990	11,735	99	35,400	426	340,650
Purchased services	74,892	64,818	2,724	21,281	284	163,999
Interest	—	31,640	—	—	—	31,640
Depreciation and amortization	42,446	56,330	—	9,872	1,130	109,778
Other	102,936	139,897	876	11,110	1,653	256,472
Total operating expenses	<u>\$2,285,667</u>	<u>\$ 623,482</u>	<u>\$ 8,382</u>	<u>\$ 199,997</u>	<u>\$ 37,632</u>	<u>\$3,155,160</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

15. Functional Expenses (continued)

	2020					
	Healthcare Services	Management and General	Foundation	Research	Education	Total
	<i>(In Thousands)</i>					
Salaries and benefits	\$ 764,000	\$ 301,606	\$ 4,661	\$ 101,384	\$ 34,258	\$1,205,909
Claims expense	699,811	—	—	—	—	699,811
Supplies	268,376	11,935	100	22,290	315	303,016
Purchased services	68,599	52,269	2,792	15,492	115	139,267
Interest	—	25,253	—	—	—	25,253
Depreciation and amortization	60,458	30,319	—	9,061	237	100,075
Other	86,804	124,946	606	6,216	1,814	220,386
Total operating expenses	<u>\$1,948,048</u>	<u>\$ 546,328</u>	<u>\$ 8,159</u>	<u>\$ 154,443</u>	<u>\$ 36,739</u>	<u>\$2,693,717</u>

The consolidated financial statements report certain categories of expenses that are attributable to more than one supporting function. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries and benefits, which are allocated on a per full-time equivalent basis, and depreciation, which is allocated based on square footage.

16. Financial Assets and Liquidity Availability

As of December 31, 2021 and 2020, Nationwide Children's had a working capital surplus of \$579,871,000 and \$364,462,000, respectively.

Financial assets available for general expenditure within one year of the consolidated balance sheet date consist of the following:

	December 31	
	2021	2020
	<i>(In Thousands)</i>	
Financial assets:		
Cash and cash equivalents	\$ 307,740	\$ 300,140
Patient accounts receivable	367,423	251,996
Other assets	149,112	229,841
Assets limited as to use:		
Board-designated capital improvement	76,102	69,511
Board-designated other	3,781,132	3,238,594
Financial assets available for general expenditures within one year	<u>\$ 4,681,509</u>	<u>\$ 4,090,082</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

16. Financial Assets and Liquidity Availability (continued)

Nationwide Children's has certain board-designated assets limited as to use which are available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. Nationwide Children's has other assets limited as to use for donor-restricted purposes, debt service and for the professional liability captive insurance program. These assets limited as to use are not available for general expenditure within the next year and are not reflected in the amounts above. As part of Nationwide Children's liquidity management plan, cash in excess of daily requirements is invested in short-term investments and money market funds.

17. Concentration of Credit Risk

In most cases, Nationwide Children's grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of the Hospital's receivables based on receivables before price concessions from patients and third-party payors was as follows:

	December 31	
	2021	2020
Medicaid	36%	39%
Commercial	48	44
Other third-party payors	9	9
Patients' responsibility	7	8
	100%	100%

18. Net Assets with Donor Restrictions

Net assets with donor restrictions are those whose use by Nationwide Children's has been limited by donors to a specific time period or purpose or those that have been restricted by donors to be maintained by Nationwide Children's in perpetuity. Investment return is allocated to net assets

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

18. Net Assets with Donor Restrictions (continued)

without donor restrictions and net assets with donor restrictions based on the respective net asset balances and the wishes of the donor. The nature and amounts of the net assets with donor restrictions are as follows:

	December 31	
	2021	2020
	<i>(In Thousands)</i>	
Net assets with donor restrictions:		
Program support	\$ 314,460	\$ 301,685
Research	95,655	80,884
	<u>\$ 410,115</u>	<u>\$ 382,569</u>

Nationwide Children's endowment consists of approximately 200 individual, donor-restricted, funds established for various purposes. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. Nationwide Children's classifies as net assets with donor restrictions: (1) the original value of gifts donated to the permanent endowment, (2) the original value of subsequent gifts to the permanent endowment, and (3) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulations are added to the fund. Nationwide Children's considers the following factors in making a determination to appropriate or accumulate donor-restricted funds: (1) the duration and preservation of the fund, (2) the purposes of the organization and the donor-restricted endowment fund, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, (6) other resources of the organization, and (7) investment policies of the organization.

To satisfy its long-term rate-of-return objectives, Nationwide Children's relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). A diversified asset allocation is targeted that places a greater emphasis on equity-based investments to achieve long-term return objectives within prudent risk considerations. Nationwide Children's expects its endowment funds, over time, to provide an average rate of return of approximately 7% annually. Actual returns in any given year may vary from this amount.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

18. Net Assets with Donor Restrictions (continued)

Nationwide Children's has a policy of appropriating for distribution each year 5% of the spendable balance of its endowment. In establishing this policy, Nationwide Children's considered the long-term expected return on its endowment. Accordingly, over the long-term, it is expected this spending policy will allow its endowment to grow at an average of 2% annually. This is consistent with Nationwide Children's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term, as well as to provide additional real growth through new gifts and investment return.

Nationwide Children's had the following donor-restricted endowment-related activities:

	Change in Endowment Net Assets with Donor Restrictions for the Year Ended December 31	
	2021	2020
	<i>(In Thousands)</i>	
Endowment net assets, beginning of year	\$ 239,092	\$ 207,577
Investment return:		
Investment income	10,977	7,255
Unrealized gains	16,249	13,585
Total investment return	27,226	20,840
Contributions	6,962	17,303
Appropriation of endowment assets for expenditure	(8,180)	(6,628)
Endowment net assets, end of year	\$ 265,100	\$ 239,092

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

19. Subsequent Events

The Hospital has evaluated and disclosed any subsequent events through April 26, 2022, which is the date the consolidated financial statements were issued. No subsequent events were identified that required recognition or disclosure in the consolidated financial statements.

Supplementary Information

NATIONWIDE CHILDREN'S HOSPITAL, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEPARTMENT OF AGRICULTURE									
AGRICULTURAL RESEARCH-BASIC AND APPLIED RESEARCH	10.001	DAA3-19-65628-1	CRDF GLOBAL	DAA3-19-65628-1		\$14,936	\$14,936	RESEARCH AND DEVELOPMENT	\$71,513,108
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	60060409 GR102924	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60060409 GR102924		\$5,138	\$19,917	RESEARCH AND DEVELOPMENT	\$71,513,108
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	GR102924	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR102924		\$14,779	\$19,917	RESEARCH AND DEVELOPMENT	\$71,513,108
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	ORD NO. 2017-2020	COLUMBUS HEALTH DEPARTMENT	ORD NO. 2017-2020		\$518,066	\$655,385	N/A	\$0
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	PO294561/ORD NO. 2315-2021	COLUMBUS HEALTH DEPARTMENT	PO294561/ORD NO. 2315-2021		\$137,319	\$655,385	N/A	\$0
TOTAL DEPARTMENT OF AGRICULTURE						<u>\$690,238</u>			
DEPARTMENT OF DEFENSE									
SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	12.351	60075912	THE OHIO STATE UNIVERSITY	60075912		\$16,451	\$16,451	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810324				\$45,277	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810546				\$153,001	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810518			\$347,600	\$1,009,994	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810547			\$169,820	\$289,436	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910371				\$238,788	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2010340			\$46,364	\$146,081	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2110278				\$65,719	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH17-1-0420				\$109,176	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	NTRAP-18-04	NATIONAL TRAUMA INSTITUTE	NTRAP-18-04		\$34,955	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	417439/URFAO: GR510697	UNIVERSITY OF ROCHESTER	417439/URFAO: GR510697		\$169,366	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	60065213	THE OHIO STATE UNIVERSITY	60065213		\$14,720	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	2005081209	THE JOHNS HOPKINS UNIVERSITY	2005081209		\$26,719	\$2,303,232	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR00112020032			\$29,499	\$139,341	\$139,341	RESEARCH AND DEVELOPMENT	\$71,513,108
TOTAL DEPARTMENT OF DEFENSE						<u>\$593,283</u>	<u>\$2,459,024</u>		
DEPARTMENT OF JUSTICE									
SERVICES FOR TRAFFICKING VICTIMS	16.320	2019-MU-BX-0156	OFFICE FOR VICTIMS OF CRIME	2019-MU-BX-0156	\$13,219	\$202,793	\$202,793	RESEARCH AND DEVELOPMENT	\$71,513,108
CRIME VICTIM ASSISTANCE	16.575	2018-VOCA-109853871	CRIME VICTIMS ASSITANCE	2018-VOCA-109853871	\$15,587	\$15,587	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2020-VOCA-132923982	CRIME VICTIMS ASSITANCE	2020-VOCA-132923982		\$1,248	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2021-VOCA-133977029	CRIME VICTIMS ASSITANCE	2021-VOCA-133977029		\$204,174	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2021-SVAA-133977032	CRIME VICTIMS ASSITANCE	2021-SVAA-133977032		\$8,707	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2021-SVAA-133977585	CRIME VICTIMS ASSITANCE	2021-SVAA-133977585	\$61,422	\$61,422	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2021-VOCA-133977596	CRIME VICTIMS ASSITANCE	2021-VOCA-133977596	\$144,164	\$144,164	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022-VOCA-134719414	CRIME VICTIMS ASSITANCE	2022-VOCA-134719414		\$43,072	\$480,662	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2022-SVAA-134719417	CRIME VICTIMS ASSITANCE	2022-SVAA-134719417		\$2,288	\$480,662	N/A	\$0
DRUG COURT DISCRETIONARY GRANT PROGRAM	16.585	RESOLUTION 21-0628	MONTGOMERY CNTY JUVENILE COURT	RESOLUTION 21-0628		\$8,414	\$13,991	RESEARCH AND DEVELOPMENT	\$71,513,108
DRUG COURT DISCRETIONARY GRANT PROGRAM	16.585	RESOLUTION 20210502	MONTGOMERY CNTY JUVENILE COURT	RESOLUTION 20210502		\$5,577	\$13,991	RESEARCH AND DEVELOPMENT	\$71,513,108
GRANTS TO ENCOURAGE ARREST POLICIES AND ENFORCEMENT OF PROTECTION ORDERS PROGRAM	16.590	60-ICIRP-BP	FRANKLIN COUNTY OFFICE OF JUSTICE POLICY AND PROGRAMS	60-ICIRP-BP		\$3,715	\$3,715	RESEARCH AND DEVELOPMENT	\$71,513,108
EDWARD BYRNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	16.738	2019-JG-E01-6378	OH OFC OF CRIMINAL JUSTICE SVC FRANKLIN COUNTY OFFICE OF JUSTICE POLICY AND PROGRAMS	2019-JG-E01-6378		\$23,071	\$23,071	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILDREN OF INCARCERATED PARENTS	16.831	303019		303019		\$33,351	\$33,351	N/A	\$0
TOTAL DEPARTMENT OF JUSTICE						<u>\$234,392</u>	<u>\$757,583</u>		
DEPARTMENT OF TREASURY									
COVID-19 CORONAVIRUS RELIEF FUND	21.019	2020-CARES-78	CRIME VICTIMS ASSITANCE	2020-CARES-78		\$34,543	\$137,064	N/A	\$0
COVID-19 CORONAVIRUS RELIEF FUND	21.019	2020-CARES-14	CRIME VICTIMS ASSITANCE	2020-CARES-14		\$25,094	\$137,064	N/A	\$0
COVID-19 CORONAVIRUS RELIEF FUND	21.019	2020-CARES-95	CRIME VICTIMS ASSITANCE	2020-CARES-95		\$50,000	\$137,064	N/A	\$0
COVID-19 CORONAVIRUS RELIEF FUND	21.019	CORONAVIRUS RELIEF	CITY OF COLUMBUS	CORONAVIRUS RELIEF		\$27,427	\$137,064	N/A	\$0
TOTAL DEPARTMENT OF TREASURY						<u>\$137,064</u>			

NATIONAL SCIENCE FOUNDATION

COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1761880			\$25,871	\$25,871	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOLOGICAL SCIENCES	47.074	2120949			\$14,795	\$227,039	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOLOGICAL SCIENCES	47.074	5506-NCH-NSF-9072	THE PENNSYLVANIA STATE UNIVERSITY	5506-NCH-NSF-9072	\$163,091	\$227,039	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOLOGICAL SCIENCES	47.074	420-41-27A	IOWA STATE UNIVERSITY	420-41-27A	\$49,153	\$227,039	RESEARCH AND DEVELOPMENT	\$71,513,108
TOTAL NATIONAL SCIENCE FOUNDATION					\$252,910			

DEPARTMENT OF EDUCATION

TRIO UPWARD BOUND	84.047	P047M170582 - 20			\$276,186	\$375,332	N/A	\$0
TRIO UPWARD BOUND	84.047	P047M170582 - 21			\$99,146	\$375,332	N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	2218	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	2218	\$37,392	\$51,867	RESEARCH AND DEVELOPMENT	\$71,513,108
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	2216	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	2216	\$14,475	\$51,867	RESEARCH AND DEVELOPMENT	\$71,513,108
TOTAL DEPARTMENT OF EDUCATION					\$427,199			

DEPARTMENT OF HEALTH AND HUMAN SERVICES

TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	60079488	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60079488	\$222,622	\$440,627	N/A	\$0
TRAINING IN GENERAL, PEDIATRIC, AND PUBLIC HEALTH DENTISTRY	93.059	60079488 GR123656	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60079488 GR123656	\$218,005	\$440,627	N/A	\$0
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.069	34225	OHIO DEPARTMENT OF HEALTH	34225	\$-38,631	\$325,285	RESEARCH AND DEVELOPMENT	\$71,513,108
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.069	34225	OHIO DEPARTMENT OF HEALTH	34225	\$148,523	\$325,285	RESEARCH AND DEVELOPMENT	\$71,513,108
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.069	34225	OHIO DEPARTMENT OF HEALTH	34225	\$99,459	\$325,285	RESEARCH AND DEVELOPMENT	\$71,513,108
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.069	34225	OHIO DEPARTMENT OF HEALTH	34225	\$63,677	\$325,285	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	CDC 19-20-436	HEMOPHILIA FOUNDATION OF MICHIGAN	CDC 19-20-436	-\$5,672	\$18,060	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	CDC 436 20-21	HEMOPHILIA FOUNDATION OF MICHIGAN	CDC 436 20-21	\$23,732	\$18,060	RESEARCH AND DEVELOPMENT	\$71,513,108
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$138	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$153,557	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$142,633	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$12,170	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$12,238	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$12,009	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	\$10,704	\$494,813	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	90AP2678NCH	OHIO HEALTH RESEARCH INSTITUTE	90AP2678NCH	\$151,364	\$494,813	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U01FD006883-01 REVISED			\$43,487	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	7R01FD006352-02			\$92,136	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	5R01FD006352-03			\$55,346	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	000508836-002	UNIVERSITY OF AL AT BIRMINGHAM	000508836-002	-\$17,842	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	123900	NEW YORK MEDICAL COLLEGE	123900	\$14,731	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678	\$9,336	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678	-\$6,533	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678	\$2,684	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	GRT-00000248	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000248	\$10,176	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	GRT-00000249	CHILDREN'S HOSPITAL OF PHILADELPHIA	GRT-00000249	\$1,973	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
OUTCOMES FOLLOWING TYMPANOSTOMY	93.103	GRT-00000424	THE CHILDREN'S HOSPITAL OF PA	GRT-00000424	\$4,994	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	125935UB	INSTITUTE	125935UB	\$434	\$210,922	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60077061	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60077061	\$61,450	\$263,858	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MCHB 436 20-21	HEMOPHILIA FOUNDATION OF MICHIGAN	MCHB 436 20-21	\$14,521	\$263,858	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MCHB 436 21-22	HEMOPHILIA FOUNDATION OF MICHIGAN	MCHB 436 21-22	\$9,691	\$263,858	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	GR124424/SPC-1000005299	THE OHIO STATE UNIVERSITY	GR124424/SPC-1000005299	\$25,871	\$263,858	N/A	\$0

MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	1 R40MC37541-01-00			\$75,003	\$263,858	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	1 R40MC41749-01-00			\$47,098	\$263,858	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60078551	THE OHIO STATE UNIVERSITY	60078551	\$163	\$263,858	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60079696	THE OHIO STATE UNIVERSITY	60079696	\$4,642	\$263,858	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	RPPN	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	RPPN	\$25,419	\$263,858	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1U01DE030065-01A1			\$8,484	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	7R01DE027091-03			\$169,067	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	SPC-1000004902/GR120606	THE OHIO STATE UNIVERSITY	SPC-1000004902/GR120606	\$24,359	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	GR123270	THE OHIO STATE UNIVERSITY	GR123270	\$11,843	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1044863-10	THE UNIVERSITY OF UTAH	1044863-10	-\$43,509	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	10044863-10	THE UNIVERSITY OF UTAH	10044863-10	\$61,872	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	10044863-10	THE UNIVERSITY OF UTAH	10044863-10	\$82,846	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295	\$365	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295	\$36,345	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295	\$83,851	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	12282SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12282SUB	\$9,145	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	12282SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12282SUB	\$20,473	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	SITZMAN-20-04	PHOENIX CHILDREN'S HOSPITAL	SITZMAN-20-04	\$21,125	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	SITZMAN-20-04	PHOENIX CHILDREN'S HOSPITAL	SITZMAN-20-04	\$45,812	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL DISEASES AND DISORDERS RESEARCH	93.121	311003	CHILDREN'S HOSPITAL MEDICAL CENTER	311003	\$51	\$532,129	RESEARCH AND DEVELOPMENT	\$71,513,108
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	EIIC	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	EIIC	\$22,749	\$650,199	N/A	\$0
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 U03MC28844-06-00			\$286,435	\$499,401	RESEARCH AND DEVELOPMENT	\$71,513,108
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 U03MC28844-07-00			\$30,957	\$128,049	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-02-00			\$1,643	\$96,910	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-02-00				\$100,816	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-02-00			\$40,961	\$85,699	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-02-00				\$19,636	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-02-00			\$11,498	\$31,623	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-02-00				\$19,696	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$83,045	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$69,215	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00			\$13,389	\$53,210	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$28,331	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$14,098	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	5 R49CE003074-03-00				\$8,491	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R01CE003349-01-00				\$22,420	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	10045261-03	THE UNIVERSITY OF UTAH	10045261-03	\$13,263	\$710,918	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	RESS14916	CASE WESTERN RESERVE UNIVERSITY	RESS14916	\$34,558	\$710,918	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	RESS14916	CASE WESTERN RESERVE UNIVERSITY	RESS14916	\$24,962	\$710,918	RESEARCH AND DEVELOPMENT	\$71,513,108
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	RESS14916	CASE WESTERN RESERVE UNIVERSITY	RESS14916	\$4,945	\$710,918	RESEARCH AND DEVELOPMENT	\$71,513,108
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	FCPH - COVID HEALTH LITERACY	FRANKLIN COUNTY BOARD OF PUBLIC HEALTH	FCPH - COVID HEALTH LITERACY	\$106,435	\$359,016	N/A	\$0
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	1 CPIMP201202-01-00			\$4,729	\$209,076	RESEARCH AND DEVELOPMENT	\$71,513,108
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	5 CPIMP201202-02-00				\$43,505	RESEARCH AND DEVELOPMENT	\$71,513,108
HUMAN GENOME RESEARCH	93.172	1K01HG011062-01				\$43,544	RESEARCH AND DEVELOPMENT	\$71,513,108
HUMAN GENOME RESEARCH	93.172	5K01HG011062-02				\$75,399	RESEARCH AND DEVELOPMENT	\$71,513,108
HUMAN GENOME RESEARCH	93.172	7K99HG010157-03				\$41,822	RESEARCH AND DEVELOPMENT	\$71,513,108
HUMAN GENOME RESEARCH	93.172	4R00HG010157-04				\$136,851	RESEARCH AND DEVELOPMENT	\$71,513,108

HUMAN GENOME RESEARCH	93.172	1R35HG011949-01			\$102,645	\$400,261	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-09			-\$739	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-09			\$50	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-10			\$133,188	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-10			\$127,911	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2R01DC003915-21A1			\$163,002	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2R01DC003915-21A1			\$20,038	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	2R01DC003915-21A1			\$43,875	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC003915-20			\$52,504	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC015688-05			\$241,992	\$431,772	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60057049-NCH	THE OHIO STATE UNIVERSITY	60057049-NCH	\$2,563	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60057049-NCH	THE OHIO STATE UNIVERSITY	60057049-NCH	\$0	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60057049-NCH	THE OHIO STATE UNIVERSITY	60057049-NCH	\$5,392	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60075934	THE OHIO STATE UNIVERSITY	60075934	\$18	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60069912	THE OHIO STATE UNIVERSITY	60069912	\$17,804	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60070611	THE OHIO STATE UNIVERSITY	60070611	\$75	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60072801	THE OHIO STATE UNIVERSITY	60072801	\$53,268	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	SPC-1000003922 GR116989	THE OHIO STATE UNIVERSITY	SPC-1000003922 GR116989	\$30,906	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60072793	THE OHIO STATE UNIVERSITY	60072793	\$21,011	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	10041913-039	THE UNIVERSITY OF UTAH	10041913-039	\$1,112	\$1,103,750	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	4R33AT009632-03			\$180,249	\$276,493	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5R33AT009632-04			\$81,611	\$276,493	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1R34AT011218-01A1			\$14,633	\$276,493	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	FY20.861.001	UNIVERSITY OF COLORADO DENVER	FY20.861.001	-\$906	\$9,870	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	FY20.861.001	UNIVERSITY OF COLORADO DENVER	FY20.861.001	\$4,073	\$9,870	RESEARCH AND DEVELOPMENT	\$71,513,108
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	FY20.861.001	UNIVERSITY OF COLORADO DENVER	FY20.861.001	\$6,703	\$9,870	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	3210920620	CHILDREN'S HOSPITAL OF PHILADELPHIA	3210920620	\$12,414	\$12,414	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	5R21MH116206-02			\$2,845	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH117594-02			-\$2,489	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH117594-03			\$248,758	\$344,289	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH117594-04			\$135,309	\$238,870	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	1R01MH123746-01A1			\$39,556	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	20002463	MCMASTER UNIVERSITY	20002463	-\$9,228	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	568947	UNIVERSITY OF PENNSYLVANIA	568947	-\$1,195	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	568947	UNIVERSITY OF PENNSYLVANIA	568947	\$12,648	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	1363	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	1363	\$73,844	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	1855	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	1855	\$314,805	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	60067394	THE OHIO STATE UNIVERSITY	60067394	\$29,992	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
MENTAL HEALTH RESEARCH GRANTS	93.242	12683SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	12683SUB	\$80,912	\$1,119,159	RESEARCH AND DEVELOPMENT	\$71,513,108
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	1H79SM084968-01			\$52,831	\$52,831	RESEARCH AND DEVELOPMENT	\$71,513,108
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4BHS154711200			\$259,193	\$373,306	N/A	\$0
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4BHS15471-13-00			\$81,046	\$373,306	N/A	\$0
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	1 H4CHS37365-01-00			\$33,067	\$373,306	RESEARCH AND DEVELOPMENT	\$71,513,108
ALCOHOL RESEARCH PROGRAMS	93.273	1R01AA027502-01A1			\$75,754	\$459,961	RESEARCH AND DEVELOPMENT	\$71,513,108
ALCOHOL RESEARCH PROGRAMS	93.273	5R01AA027502-02			\$354,701	\$459,961	RESEARCH AND DEVELOPMENT	\$71,513,108
ALCOHOL RESEARCH PROGRAMS	93.273	GR122831	THE OHIO STATE UNIVERSITY	GR122831	\$29,506	\$459,961	RESEARCH AND DEVELOPMENT	\$71,513,108
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R01DA042948-03			\$67,995	\$601,959	RESEARCH AND DEVELOPMENT	\$71,513,108
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1R01DA052580-01A1			\$70,586	\$601,959	RESEARCH AND DEVELOPMENT	\$71,513,108
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	SPC-1000005500	THE OHIO STATE UNIVERSITY	SPC-1000005500	\$2,300	\$601,959	RESEARCH AND DEVELOPMENT	\$71,513,108

DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	GR122007 / SPC-1000004551	THE OHIO STATE UNIVERSITY	GR122007 / SPC-1000004551	\$427,651	\$601,959	RESEARCH AND DEVELOPMENT	\$71,513,108
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	GR122009 / SPC-1000004557	THE OHIO STATE UNIVERSITY	GR122009 / SPC-1000004557	\$29,940	\$601,959	RESEARCH AND DEVELOPMENT	\$71,513,108
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1009-55811085045103-1100000018	WAKE FOREST UNIVERSITY HEALTH SCIENCES	1009-55811085045103-1100000018	\$3,487	\$601,959	RESEARCH AND DEVELOPMENT	\$71,513,108
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R21EB026518-03			\$209,569	\$305,302	RESEARCH AND DEVELOPMENT	\$71,513,108
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R21EB026518-03S1			\$61,208	\$74,708	RESEARCH AND DEVELOPMENT	\$71,513,108
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1090547-401786	CARNEGIE MELLON UNIVERSITY	1090547-401786	\$21,025	\$305,302	RESEARCH AND DEVELOPMENT	\$71,513,108
TEENAGE PREGNANCY PREVENTION PROGRAM	93.297	1 TP1AH000212-01-00			\$95,246	\$472,096	RESEARCH AND DEVELOPMENT	\$71,513,108
TEENAGE PREGNANCY PREVENTION PROGRAM	93.297	5 TP1AH000212-02-00				\$303,448	RESEARCH AND DEVELOPMENT	\$71,513,108
		5R21MD011767-						
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	02/3R21MD011767			-\$139	\$454,671	RESEARCH AND DEVELOPMENT	\$71,513,108
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R01MD013881-02			\$3,585	\$454,671	RESEARCH AND DEVELOPMENT	\$71,513,108
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R01MD013881-03			\$300,953	\$454,671	RESEARCH AND DEVELOPMENT	\$71,513,108
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1R21MD015860-01			\$35,011	\$85,558	RESEARCH AND DEVELOPMENT	\$71,513,108
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R21MD015860-02			\$42,099	\$454,671	RESEARCH AND DEVELOPMENT	\$71,513,108
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	RF00205-2020-0290	UNIV OF TX HEALTH SCIENCE CTR	RF00205-2020-0290	\$12,583	\$454,671	RESEARCH AND DEVELOPMENT	\$71,513,108
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	RF00235-2021-0350	UNIV OF TX HEALTH SCIENCE CTR	RF00235-2021-0350	\$10,032	\$454,671	RESEARCH AND DEVELOPMENT	\$71,513,108
			NEW YORK UNIVERSITY SCHOOL OF MEDICINE					
TRANS-NIH RESEARCH SUPPORT	93.310	19-A0-00-1003237		19-A0-00-1003237	\$6,504	\$19,400	RESEARCH AND DEVELOPMENT	\$71,513,108
			NEW YORK UNIVERSITY SCHOOL OF MEDICINE					
TRANS-NIH RESEARCH SUPPORT	93.310	19-A0-00-1003237		19-A0-00-1003237	\$4,054	\$19,400	RESEARCH AND DEVELOPMENT	\$71,513,108
			UNIVERSITY OF NEW MEXICO FOR ITS HEALTH SCIENCES CENTER					
TRANS-NIH RESEARCH SUPPORT	93.310	3RGH1		3RGH1	\$8,842	\$19,400	RESEARCH AND DEVELOPMENT	\$71,513,108
DIETARY SUPPLEMENT RESEARCH PROGRAM	93.321	1R01HD102439-01A1			\$65,407	\$65,407	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$204,538	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$5,033	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$13,158	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$48,041	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$37,213	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$18,447	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60075738	\$57,000	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322	\$230,562	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322	\$13,674	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	SPC-1000004979 / GR123322	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	SPC-1000004979 / GR123322	\$5,125	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	203-7853	DUKE UNIVERSITY	203-7853	\$1,183	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60075738	THE OHIO STATE UNIVERSITY CCTS	60075738	\$15,626	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	CCTS PILOT GRANT	THE OHIO STATE UNIVERSITY CCTS	CCTS PILOT GRANT	\$8,491	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	FP00010833_SA002	VIRGINIA COMMONWEALTH UNIVERSITY	FP00010833_SA002	\$5,319	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	FP00010833_SA002	VIRGINIA COMMONWEALTH UNIVERSITY	FP00010833_SA002	\$4,970	\$668,380	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U01CA232488-01			\$121,116	\$577,923	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA231641-01			\$880,550	\$1,746,319	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$122,496	\$198,455	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$142,497	\$531,223	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$143,396	\$380,092	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$228,553	\$4,313,900	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1			\$87,834	\$524,128	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	3U54CA232561-01A1S1			\$51,207	\$4,313,900	RESEARCH AND DEVELOPMENT	\$71,513,108
21ST CENTURY CURES ACT - BEAU BIDEN CANCER	93.353	320138021-S1	THE CHILDREN'S HOSPITAL OF PA	320138021-S1	\$76,000	\$4,313,900	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	5R01NR017533-03			\$247,143	\$299,262	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	5R01NR017533-04			\$136,449	\$406,903	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	1K99NR019115-01A1			\$52,497	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	5K99NR019115-02			\$27,675	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	60067619	THE OHIO STATE UNIVERSITY	60067619	\$16,473	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	1300204	DANA FARBER CANCER INSTITUTE	1300204	\$1,788	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	1300205	DANA FARBER CANCER INSTITUTE	1300205	\$5,638	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
			CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER					
NURSING RESEARCH	93.361	304482		304482	\$34,353	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108

NURSING RESEARCH	93.361	304482	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	304482	\$48,617	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	305174	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	305174	\$970	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	204-100720-550114	WAKE FOREST UNIVERSITY HEALTH SCIENCES	204-100720-550114	\$25,886	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
NURSING RESEARCH	93.361	204-55811085045116- 10000550114	WAKE FOREST UNIVERSITY HEALTH SCIENCES	204-55811085045116-10000550114	\$36,019	\$956,081	RESEARCH AND DEVELOPMENT	\$71,513,108
INTEGRATED CARE FOR KIDS MODEL	93.378	2B2CMS331798-01-00	CENTERS FOR MEDICARE & MEDICAID SERVICES	2B2CMS331798-01-00	\$42,088	\$1,070,979	RESEARCH AND DEVELOPMENT	\$71,513,108
INTEGRATED CARE FOR KIDS MODEL	93.378	2B2CMS331798-02-00	CENTERS FOR MEDICARE & MEDICAID SERVICES	2B2CMS331798-02-00	\$149,671	\$1,028,891	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R21CA227926-02			\$30,850	\$268,274	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R21CA227926-02			\$56,829	\$268,274	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA248103-01A1			\$135,240	\$268,274	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R01CA248103-01A1S2			\$22,750	\$268,274	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R01CA248103-01A1S1			\$22,605	\$268,274	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-05			-\$679	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-05			\$636	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-05			\$4	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-05			\$1	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-05			-\$13	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-05			\$1	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1UM1CA239754-01			-\$17	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA239754-02			\$285,873	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA239754-03			\$641,623	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			\$951,103	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			\$1,344	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			-\$15	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			\$37,710	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			\$14,611	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			\$13,771	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196173-06 REVISED			\$344,443	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$2,491,758	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$2,604	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$385	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$170,801	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$291	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$187,709	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$54,870	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196173-07			\$81,436	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1U24CA254445-01			\$941,518	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA254445-02			\$1,258,208	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196175-06			\$1,577,306	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U24CA196175-06			\$60,455	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-07			\$264,331	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U24CA196175-07			\$136,275	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205601	DANA FARBER CANCER INSTITUTE	1205601	-\$1	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205603	DANA FARBER CANCER INSTITUTE	1205603	\$107,955	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205604	DANA FARBER CANCER INSTITUTE	1205604	\$180,895	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	60066393	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60066393	\$35,233	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	GR111019 SPC-1000003753	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR111019 SPC-1000003753	\$8,613	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ	\$386,086	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ	\$35,671	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ	\$1,175,200	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	BSB06-RAMIREZ	NRG ONCOLOGY	BSB06-RAMIREZ	\$123,730	\$13,788,810	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	5R21CA223104-02			\$54,518	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AALL1131	CHILDREN'S HOSPITAL OF PHILADELPHIA	AALL1131	-\$2,882	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AALL0932 11XS197	CHILDREN'S HOSPITAL OF PHILADELPHIA	AALL0932 11XS197	-\$1,383	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	111287260-7914879	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287260-7914879	-\$975	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	111287270-7969226	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287270-7969226	\$41,776	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	60059472	THE OHIO STATE UNIVERSITY	60059472	\$20,397	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	60059472	THE OHIO STATE UNIVERSITY	60059472	\$45,762	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	201601437-03	UC DAVIS MEDICAL CENTER	201601437-03	-\$185	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	RGF011027-A	CHILDREN'S HOSPITAL OF LOS ANGELES	RGF011027-A	-\$5,302	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	000518779-SC001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518779-SC001	\$118,590	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	9500080220-06C	PUBLIC HEALTH INSTITUTE	9500080220-06C	\$1	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	9500080220-06C	PUBLIC HEALTH INSTITUTE	9500080220-06C	\$10,736	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03996	PUBLIC HEALTH INSTITUTE	AR03996	\$30,779	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026529 SUB425_02	PUBLIC HEALTH INSTITUTE	FP00026529 SUB425_02	\$1,627	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03219	PUBLIC HEALTH INSTITUTE	AR03219	\$13,336	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108

CANCER TREATMENT RESEARCH	93.395	1013080-0004_NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-0004_NATIONWIDE		\$1,466	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	1013080-0004_NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-0004_NATIONWIDE		\$3,250	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	20126869 - RSUB	PUBLIC HEALTH INSTITUTE	20126869 - RSUB		\$2,520	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03755	PUBLIC HEALTH INSTITUTE	AR03755		\$12,441	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	950080221-XX	PUBLIC HEALTH INSTITUTE	950080221-XX		\$3,088	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03293	PUBLIC HEALTH INSTITUTE	AR03293		\$6,970	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	60070505-NCH	THE OHIO STATE UNIVERSITY	60070505-NCH		\$50,805	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00029869_SUB02_02	PUBLIC HEALTH INSTITUTE	FP00029869_SUB02_02		\$25,793	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03745	PUBLIC HEALTH INSTITUTE	AR03745		\$126,528	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	ACNS1422 / 20126538 - RSUB	PUBLIC HEALTH INSTITUTE	ACNS1422 / 20126538 - RSUB		\$19,645	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03752	PUBLIC HEALTH INSTITUTE	AR03752		\$69,644	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00029870_SUB01_02	PUBLIC HEALTH INSTITUTE	FP00029870_SUB01_02		\$30,241	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03764	PUBLIC HEALTH INSTITUTE	AR03764		\$157,985	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00029861_SUB02_02	PUBLIC HEALTH INSTITUTE	FP00029861_SUB02_02		\$583	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03769	PUBLIC HEALTH INSTITUTE	AR03769		\$2,981	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00029860_SUB02_02	PUBLIC HEALTH INSTITUTE	FP00029860_SUB02_02		\$6,792	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03765	PUBLIC HEALTH INSTITUTE	AR03765		\$9,792	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB614_02	PUBLIC HEALTH INSTITUTE	FP00026529_SUB614_02		\$3,783	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR04539	PUBLIC HEALTH INSTITUTE	AR04539		\$6,491	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB92_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00026529_SUB92_01	\$208	\$3,940	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB267_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00026529_SUB267_01		\$33,499	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	9500090219 / 20083454	CHILDREN'S HOSPITAL OF PHILADELPHIA	9500090219 / 20083454		\$1,761	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026101_SUB01_02	PUBLIC HEALTH INSTITUTE	FP00026101_SUB01_02		\$6,385	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03746	PUBLIC HEALTH INSTITUTE	AR03746		\$11,635	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00027059_SUB02_01	PUBLIC HEALTH INSTITUTE	FP00027059_SUB02_01		-\$948	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB504_02	THE CHILDREN'S HOSPITAL OF PA	FP00026529_SUB504_02		\$15,272	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB541_02	THE CHILDREN'S HOSPITAL OF PA	FP00026529_SUB541_02		\$7,657	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	NCTN ITSC-HM 9500130221-XX	THE CHILDREN'S HOSPITAL OF PA	NCTN ITSC-HM 9500130221-XX		\$4,163	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00026537_SUB13_03	THE CHILDREN'S HOSPITAL OF PA	FP00026537_SUB13_03		\$7,929	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	2(GG015224-01)	TRUSTEES OF COLUMBIA UNIV NY	2(GG015224-01)		\$4,540	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	20127343 - RSUB/9500080221-S18	PUBLIC HEALTH INSTITUTE	20127343 - RSUB/9500080221-S18		\$11,262	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03759 AR04918	PUBLIC HEALTH INSTITUTE	AR03759 AR04918		\$7,425	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00030519_SUB28_01	THE CHILDREN'S HOSPITAL OF PA	FP00030519_SUB28_01		\$258	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	S01426-01	THE UNIVERSITY OF IOWA	S01426-01		\$11,383	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	S01426-01	THE UNIVERSITY OF IOWA	S01426-01		\$2,809	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	GMO NO. 200202	UT SOUTHWESTERN MEDICAL CENTER	GMO NO. 200202		-\$469	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	GY012-RAMIREZ-GY7	NRG ONCOLOGY FOUNDATION	GY012-RAMIREZ-GY7		\$12,657	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	GY012-RAMIREZ-GY7	NRG ONCOLOGY FOUNDATION	GY012-RAMIREZ-GY7		\$229	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	SARC037-5	SARCOMA ALLIANCE FOR RESEARCH THROUGH	SARC037-5		\$5,858	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	111287261-7951318	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287261-7951318		\$38,588	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	110068210-7957794	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	110068210-7957794		\$24,305	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	110068220-7997444	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	110068220-7997444		\$27,747	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	GRT-00000636	THE CHILDREN'S HOSPITAL OF PA	GRT-00000636		\$43,913	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	1013080-014_NATIONWIDE	OREGON HEALTH SCIENCES UNIVERSITY	1013080-014_NATIONWIDE		\$904	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	ACCL1633 GRT-00000608	CHILDREN'S HOSPITAL OF PHILADELPHIA	ACCL1633 GRT-00000608		\$1,182	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	ANBL1232 / 9500080221-S2	THE CHILDREN'S HOSPITAL OF PA	ANBL1232 / 9500080221-S2		\$20,029	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR06695	PUBLIC HEALTH INSTITUTE	AR06695		\$839	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR06698	PUBLIC HEALTH INSTITUTE	AR06698		\$343	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	FP00033922_SUB131_01	THE CHILDREN'S HOSPITAL OF PA	FP00033922_SUB131_01		\$1,075	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03762	PUBLIC HEALTH INSTITUTE	AR03762		\$2,328	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03269	PUBLIC HEALTH INSTITUTE	AR03269		\$19,313	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	AR03418	PUBLIC HEALTH INSTITUTE	AR03418		\$10,592	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER TREATMENT RESEARCH	93.395	SUB TO U10CA180886	PUBLIC HEALTH INSTITUTE	SUB TO U10CA180886		\$805	\$1,206,801	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER BIOLOGY RESEARCH	93.396	1R03CA259865-01				\$43,912	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER BIOLOGY RESEARCH	93.396	1R01CA247941-01A1				\$231,529	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER BIOLOGY RESEARCH	93.396	SUP1601	CHILDREN'S HOSPITAL OF LOS ANGELES	SUP1601		-\$138	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER BIOLOGY RESEARCH	93.396	10037968-NCH	THE UNIVERSITY OF UTAH	10037968-NCH		\$3,409	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER BIOLOGY RESEARCH	93.396	A00-4018-S001	MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-4018-S001		\$183	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER BIOLOGY RESEARCH	93.396	A00-4018-S001	MEDICAL UNIVERSITY OF SOUTH CAROLINA	A00-4018-S001		\$8,402	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108

WASHINGTON UNIVERSITY IN ST. LOUIS									
CANCER BIOLOGY RESEARCH	93.396	WU-20-405		WU-20-405		-\$416	\$286,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CENTERS SUPPORT GRANTS	93.397	60069547	THE OHIO STATE UNIVERSITY	60069547		-\$866	\$75,254	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CENTERS SUPPORT GRANTS	93.397	60069547	THE OHIO STATE UNIVERSITY	60069547		-\$1,439	\$75,254	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CENTERS SUPPORT GRANTS	93.397	S02159-01	THE UNIVERSITY OF IOWA	S02159-01		\$66,207	\$75,254	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CENTERS SUPPORT GRANTS	93.397	SPC-1000005696 / GR121877	THE OHIO STATE UNIVERSITY	SPC-1000005696 / GR121877		\$11,352	\$75,254	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER RESEARCH MANPOWER	93.398	SK08CA201638-05				\$123,438	\$334,664	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER RESEARCH MANPOWER	93.398	SK08CA237338-02				\$68,882	\$334,664	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER RESEARCH MANPOWER	93.398	SK08CA237338-03				\$120,651	\$334,664	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER RESEARCH MANPOWER	93.398	GR124657 SPC-1000005411	OHIO STATE UNIVERSITY ILAB	GR124657 SPC-1000005411		\$21,693	\$334,664	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CONTROL	93.399	FP00028127_SUB236_01	THE CHILDREN'S HOSPITAL OF PA	FP00028127_SUB236_01		\$3,808	\$5,166	RESEARCH AND DEVELOPMENT	\$71,513,108
			CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00034095_SUB71_01		\$1,112	\$5,166	RESEARCH AND DEVELOPMENT	\$71,513,108
CANCER CONTROL	93.399	FORTE-RAMIREZ-GY8	NRG ONCOLOGY FOUNDATION	FORTE-RAMIREZ-GY8		\$246	\$5,166	RESEARCH AND DEVELOPMENT	\$71,513,108
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	PI-CD33-PCOR	TASK FORCE GLOBAL HEALTH INC	PI-CD33-PCOR		\$12,753	\$12,753	RESEARCH AND DEVELOPMENT	\$71,513,108
NON-ACA/PPHF BUILDING CAPACITY OF THE PUBLIC HEALTH SYSTEM TO IMPROVE POPULATION HEALTH THROUGH NATIONAL NONPROFIT ORGANIZATIONS	93.424	CDC7073-0-0183-1	CHANGELAB SOLUTIONS	CDC7073-0-0183-1		\$2,088	\$2,088	RESEARCH AND DEVELOPMENT	\$71,513,108
PROVIDER RELIEF FUNDS	93.498	COVID-19				\$81,583,962	\$81,583,962	N/A	\$0
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	G-2021-22-0228-01	OHIO CHILDRENS TRUST FUND	G-2021-22-0228-01	\$143,000	\$188,176	\$640,650	N/A	\$0
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	G-2021-22-0228-01	OHIO CHILDRENS TRUST FUND	G-2021-22-0228-01	\$216,071	\$419,304	\$640,650	N/A	\$0
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	2001OHTANF	BOYS & GIRLS CLUBS OH ALLIANCE	2001OHTANF		\$30,796	\$640,650	RESEARCH AND DEVELOPMENT	\$71,513,108
			FRANKLIN COUNTY DEPARTMENT OF JOB AND FAMILY SERVICES	25-21-3536		\$2,374	\$640,650	RESEARCH AND DEVELOPMENT	\$71,513,108
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	25-21-3536				\$4,733	\$42,857	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2021-22-0228-01	OHIO CHILDRENS TRUST FUND	G-2021-22-0228-01		\$42,857	\$219,991	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246	OHIO CHILDRENS TRUST FUND	G-2223-22-0246		\$42,018	\$219,991	N/A	\$0
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2223-22-0246	OHIO CHILDRENS TRUST FUND	G-2223-22-0246		\$135,116	\$219,991	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	60077251 GR125049	THE OHIO STATE UNIVERSITY	60077251 GR125049		\$11,126	\$11,126	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	60072687	THE OHIO STATE UNIVERSITY	60072687		-\$35	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR120973	THE OHIO STATE UNIVERSITY	GR120973		\$18,166	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR120973	THE OHIO STATE UNIVERSITY	GR120973		\$27,280	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$47,982	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$67,872	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR124661	THE OHIO STATE UNIVERSITY	GR124661		\$21,342	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR12354	THE OHIO STATE UNIVERSITY	GR12354		\$4,371	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
MEDICAL ASSISTANCE PROGRAM	93.778	GR123585	THE OHIO STATE UNIVERSITY	GR123585		\$6,687	\$193,665	RESEARCH AND DEVELOPMENT	\$71,513,108
HOSPITAL PREPAREDNESS PROGRAM (HPP) EBOLA PREPAREDNESS AND RESPONSE ACTIVITIES	93.817	0000076413-1	OHIO DEPARTMENT OF HEALTH	0000076413-1		\$45,523	\$45,523	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R00HL116769-05				\$19,684	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL128847-04				-\$8	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K23HL127224-05				\$106,094	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09			\$55,448	\$55,448	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$0	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$0	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-04				\$7,192	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-04			\$16,271	\$44,978	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135657-04			\$210,172	\$372,487	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL139796-03				-\$1,983	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL139796-03			\$178,079	\$178,079	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL139796-04			\$205,778	\$606,254	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R00HL131682-05				\$142,070	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-02				\$397	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-03				\$676,489	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-04				\$42,841	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135103-04 REVISED			\$2,936	\$6,949	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135103-05			\$38,481	\$491,678	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R03HL148368-02				\$67,079	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL144009-02				\$238,958	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL144009-03				\$128,494	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	1UG3HL148693-01				\$53,717	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL146582-01A1				\$88,081	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL146582-02				\$342,112	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL155282-01				\$166,466	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	4UH3HL148693-02				\$186,021	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL157491-01				\$171,270	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1223992	UNIVERSITY AT BUFFALO	R1223992		\$140,563	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	GR119792	THE OHIO STATE UNIVERSITY	GR119792		\$5,176	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	3004465579	REGENTS UNIVERSITY OF MICHIGAN	3004465579		\$31,455	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01HL125918	YALE UNIVERSITY	R01HL125918		\$1,594	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	FUEL-OLE	NEW ENGLAND RESEARCH CENTER	FUEL-OLE		-\$21,584	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000000719	BAYLOR COLLEGE OF MEDICINE	7000000719		\$15,661	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000000719	BAYLOR COLLEGE OF MEDICINE	7000000719		\$16,900	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108

			VANDERBILT UNIVERSITY MEDICAL						
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC-68481	CENTER	VUMC-68481		\$4,846			
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R41HL145827-01A1	LYST THERAPEUTICS, LLC	1R41HL145827-01A1		\$43,904	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1227445	UNIVERSITY AT BUFFALO	R1227445		\$30,920	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1227445	UNIVERSITY AT BUFFALO	R1227445		\$92,416	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R43HL152844-01	LYST THERAPEUTICS, LLC	1R43HL152844-01		\$58,849	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	RESS15518	CASE WESTERN RESERVE UNIVERSITY	RESS15518		\$10,184	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	RESS15518	CASE WESTERN RESERVE UNIVERSITY	RESS15518		\$10,217	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000001321	BAYLOR COLLEGE OF MEDICINE	7000001321		\$13,534	\$4,645,482	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5K08HL129080-05				\$114,620	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5K08HL138460-04				\$81,652	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5K08HL138460-05				\$89,898	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5R01HL136963-03			\$4,165	\$40,141	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5R01HL136963-04			\$22,590	\$336,595	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5R00HL131682-05				\$8,258	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	1R01HL148171-01A1			\$16,932	\$115,670	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5R01HL148171-02			\$3,951	\$226,400	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	1R01HL155095-01				\$391,589	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	5R01HL155095-02				\$25,585	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	1R01HL157039-01			\$34,857	\$141,677	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	GR110932	THE OHIO STATE UNIVERSITY	GR110932		\$33,153	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	GR110932	THE OHIO STATE UNIVERSITY	GR110932		\$26,677	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	8635-NCH	INDIANA UNIVERSITY	8635-NCH		\$4,901	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	8635-NCH	INDIANA UNIVERSITY	8635-NCH		\$11,885	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	8636-NCH	INDIANA UNIVERSITY	8636-NCH		\$910	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	8636-NCH	INDIANA UNIVERSITY	8636-NCH		\$10,565	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	0008871/02262021	UNIVERSITY OF RHODE ISLAND	0008871/02262021		\$12,787	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
LUNG DISEASES RESEARCH	93.838	0008871/02262021	UNIVERSITY OF RHODE ISLAND	0008871/02262021		\$2,061	\$1,675,024	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R01HL119485-05				\$2,118	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5K23HL127303-05				\$72,172	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R03HL146877-02				\$15,003	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R21HL150487-01				\$61,244	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R21HL150487-02			\$57,519	\$117,611	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	ACRI 19-001	ALL CHILDREN'S RESEARCH INSTITUTE, INC.	ACRI 19-001		\$3,730	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	PBMTC STUDY NO. 1507	CHILDREN'S HOSPITAL OF LOS ANGELES	PBMTC STUDY NO. 1507		\$870	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1U01HL143477	THE MEDICAL COLLEGE OF WISCONSIN	1U01HL143477		\$21,383	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A412639	EMORY UNIVERSITY	A412639		\$64,702	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	A412639	EMORY UNIVERSITY	A412639		\$35,283	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1001432-NCH	VERSITI BLOOD CENTER OF WISCONSIN	1001432-NCH		\$1,821	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	6207923	THE MEDICAL COLLEGE OF WISCONSIN, INC.	6207923		\$6,248	\$397,949	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R21AR068040-02				\$1	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$0	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05			\$27,989	\$146,020	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$202,485	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$241,536	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$216,268	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$219,172	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$201,720	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$6,294	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$5,150	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$8,053	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-05				\$12,995	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR073311-03			\$144,553	\$274,351	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR073311-04				\$178,552	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR073908-01A1				\$0	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR073908-02			\$43,174	\$235,978	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR073908-03				\$227,948	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR079071-01				\$51,104	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R21AR079774-01				\$56,052	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR078395-01A1				\$141,150	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3201900722	THE CHILDREN'S HOSPITAL OF PA	3201900722		\$1,376	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	3201900722	THE CHILDREN'S HOSPITAL OF PA	3201900722		\$7	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$23,798	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$3,438	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$34,400	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$2,227	\$2,490,075	RESEARCH AND DEVELOPMENT	\$71,513,108

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK110077-05			\$89,320	\$213,878	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK102594-05				\$5,824	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK103982-05				\$53,407	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK115737-03			\$2,981	\$44,074	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK115737-04			\$78,205	\$343,834	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK114035-03				\$54,551	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK114035-04				\$177,195	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R03DK118306-02				\$72,010	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R03DK118315-02				\$40,631	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK122119-02				\$47,549	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK122119-03				\$83,034	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK100866-08			\$579,932	\$939,327	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK100866-09			\$67,800	\$233,759	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK125469-01				\$91,036	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK125469-02				\$321,553	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK122171-01A1				\$220,929	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK122171-02				\$269,983	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K01DK128379-01				\$70,132	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K01DK126991-01A1				\$37,402	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1F32DK130521-01				\$21,404	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK124549-01A1				\$70,923	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK128088-01A1				\$62,663	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7000000297	BAYLOR COLLEGE OF MEDICINE	7000000297		\$38,129	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	25460-3301820721	CHILDREN'S HOSPITAL OF PHILADELPHIA	25460-3301820721		\$2,973	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR102549 60058926	THE OHIO STATE UNIVERSITY	GR102549 60058926		\$38,465	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60071976	THE OHIO STATE UNIVERSITY	60071976		\$0	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR102549 60058926	THE OHIO STATE UNIVERSITY	GR102549 60058926		\$3,712	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M8526	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M8526		\$0	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M9121	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M9121		\$9,305	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M9121	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M9121		\$921	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60069457	THE OHIO STATE UNIVERSITY	60069457		\$15,486	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S01065-01	THE UNIVERSITY OF IOWA	S01065-01		\$443	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR118321/SPC-1000004136	THE OHIO STATE UNIVERSITY	GR118321/SPC-1000004136		\$23,986	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	GR118321/SPC-1000004136	THE OHIO STATE UNIVERSITY	GR118321/SPC-1000004136		\$3,150	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60075032	THE OHIO STATE UNIVERSITY	60075032		\$24,480	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SITE 0263 TRIALNET AFFILIATE	UNIVERSITY OF SOUTH FLORIDA	SITE 0263 TRIALNET AFFILIATE		\$14	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	8451_NCH	INDIANA UNIVERSITY	8451_NCH		\$8,486	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	8451_NCH	INDIANA UNIVERSITY	8451_NCH		\$17,376	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S02051-01	THE UNIVERSITY OF IOWA	S02051-01		\$4,650	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S02051-02	THE UNIVERSITY OF IOWA	S02051-02	\$14,564	\$3,681,238	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS085238-05			\$8,579	\$23,235	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS085238-05				\$26,312	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4R33NS101166-02				\$0	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R33NS101166-03			\$130,728	\$333,708	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS105986-01				\$16,932	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	96755C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	96755C		\$0	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	96755C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	96755C		\$11,278	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	96755C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	96755C		-\$18,398	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1600891	UNIVERSITY OF MARYLAND	1600891		-\$5,610	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 157949	UNIVERSITY OF VIRGINIA	GB10094 157949		-\$19,567	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 PO2167933	UNIVERSITY OF VIRGINIA	GB10094 PO2167933		\$7,265	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	16-8475	UNIVERSITY OF WISCONSIN AT MADISON	16-8475		\$1,103	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	CNVA00050115 (134296-6)	UNIVERSITY OF PITTSBURGH	CNVA00050115 (134296-6)		\$15,986	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NN107 - FX-LEARN	MASSACHUSETTS GENERAL HOSPITAL	NN107 - FX-LEARN		\$1,557	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	104975C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	104975C		-\$1,877	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	104975C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	104975C		\$1,402	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	104975C	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	104975C		\$157	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	60077938	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60077938		\$51,766	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GR124707	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR124707		\$24,393	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	210305-0819-02	THE JACKSON LABORATORY	210305-0819-02		\$8,145	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	S-001035	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	S-001035		\$24,591	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	S-001035	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	S-001035		\$14,885	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	110265C	UNIVERSITY OF CALIFORNIA, SAN DIEGO	110265C		\$1,202	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	432107-19D50	VIRGINIA POLYTECHNIC INSTITUTE	432107-19D50		\$7,277	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	432107-19D50	VIRGINIA POLYTECHNIC INSTITUTE	432107-19D50		\$70,305	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	10050533-03	THE UNIVERSITY OF UTAH	10050533-03		\$8,243	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	237416	MASS GENERAL BRIGHAM INC	237416		\$32,068	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	237416	MASS GENERAL BRIGHAM INC	237416		\$17,006	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5(GG015970-01)	COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE	5(GG015970-01)		\$41,730	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5(GG015970-02)	COLUMBIA UNIVERSITY SPONSORED PROJECTS FINANCE	5(GG015970-02)		\$35,275	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	412670-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412670-19D50		\$10,187	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	WSU21083 GRANT INDEX 301646	WAYNE STATE UNIVERSITY	WSU21083 GRANT INDEX 301646		\$7,362	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1(GG017672-01)	COLUMBIA UNIVERSITY MEDICAL CENTER	1(GG017672-01)		\$11,702	RESEARCH AND DEVELOPMENT	\$71,513,108
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	MAGANA	HUGO W. MOSER RI AT KENNEDY KRIEGER, INC.	MAGANA		\$40,195	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5K08A1108792-05				-\$3,637	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3R01AI093848-07S1				\$4,228	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI093848-07				\$4,404	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI093848-08				\$312,160	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI114581-05				\$57,077	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI126890-05			\$273,986	\$518,663	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01AI131313-05				\$104,099	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI124029-04				-\$10,269	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI124029-05				\$306,947	RESEARCH AND DEVELOPMENT	\$71,513,108

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05				\$20,794	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05				\$35,225	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05			\$16,194	\$16,194	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05				-\$6,969	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05				-\$56	\$56	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05				\$50,573	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01A112524-05				-\$4,228	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1125489-04			\$51,020	\$196,196	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131386-02 REVISED				\$3,322	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131386-03			-\$15,251	-\$15,251	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131386-04			\$262,543	\$291,693	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3U01A1131386-04S1			\$643,010	\$1,046,364	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01A1131386-05				\$84,662	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3U01A1131386-05S1				\$207,937	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1134848-03			\$17,285	\$20,015	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1134848-04			\$56,587	\$427,228	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1137912-02				-\$2,054	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1137567-03			\$4,983	\$82,436	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1137567-04				\$481,362	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1096882-07				-\$34,363	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1096882-08			\$171,250	\$348,031	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1096882-09				\$237,783	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139511-03			\$105,527	\$423,285	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139511-04				\$115,447	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5F30A1143060-02				-\$213	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5F30A1143060-03				\$40,377	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A116917-06				-\$17,570	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01A1116917-07A1			\$70,113	\$289,065	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1142885-02				\$88,626	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1140001-02				\$102,329	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139519-02			\$52,416	\$101,912	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1139519-03			\$189,332	\$363,889	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1142433-02				\$164,030	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1143740-02				\$3,525	\$97,520	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01A1146581-01A1				\$41,018	\$93,679	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1146581-02			\$193,037	\$347,890	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1149414-01				\$27,947	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1149414-02				\$45,747	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1153752-01				\$114,378	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1153752-02				\$48,233	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1F31A1143234-01A1				\$27,128	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01A1155501-01				\$118,140	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01A1155501-01				\$118,036	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01A1155501-01				\$65,616	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-02				\$98,045	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-02				\$31,095	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01A1155501-02				\$29,579	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1156328-01				\$126,486	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21A1156328-02				\$67	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1159735-01				\$137,245	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01A1151175-01A1				\$207,193	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1156406-01				\$63,683	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01A1114581-06				\$113,126	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21A1164077-01				\$59,827	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	S00167-01	THE UNIVERSITY OF IOWA	S00167-01		\$7,090	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	VUMCS9103	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMCS9103		\$0	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	FY18.777.001	UNIVERSITY OF COLORADO DENVER	FY18.777.001		\$0	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AWD7773224-GR205827	GEORGETOWN UNIVERSITY	AWD7773224-GR205827		\$3,443	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$5,421	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$109,514	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$8,776	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60062781	THE OHIO STATE UNIVERSITY	60062781		\$27,830	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60069338	THE OHIO STATE UNIVERSITY	60069338		\$15,876	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60069338	THE OHIO STATE UNIVERSITY	60069338		\$33,935	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0221-11	THE JACKSON LABORATORY	210310-0221-11		\$26,730	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0221-16	THE JACKSON LABORATORY	210310-0221-16		\$16,181	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0222-11	THE JACKSON LABORATORY	210310-0222-11		\$45,749	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0222-20	THE JACKSON LABORATORY	210310-0222-20		\$98,927	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1090598-424099	CARNEGIE MELLON UNIVERSITY	1090598-424099		\$40,051	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1090598-424099	CARNEGIE MELLON UNIVERSITY	1090598-424099		\$9,935	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60071577	THE OHIO STATE UNIVERSITY	60071577		\$4,563	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR115767	THE OHIO STATE UNIVERSITY	GR115767		\$20,649	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR115767 / SPC-1000003908	THE OHIO STATE UNIVERSITY CHILDREN'S HOSPITAL OF LOS ANGELES	GR115767 / SPC-1000003908		\$22,468	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	C-SIDE PBMTC 1801	ANGELES	C-SIDE PBMTC 1801		\$1,957	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108	

ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	000522211-SC008	UNIV OF ALABAMA AT BIRMINGHAM	000522211-SC008	\$3,348	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	000522211-SC008	UNIV OF ALABAMA AT BIRMINGHAM	000522211-SC008	\$1,355	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	310399	CINCINNATI CHILDREN'S HOSPITAL	310399	\$16,311	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	310399	CINCINNATI CHILDREN'S HOSPITAL	310399	\$47	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GR119216	THE OHIO STATE UNIVERSITY	GR119216	\$22,016	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	117625C	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	117625C	\$11,237	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	117625C	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	117625C	\$2,303	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	248445/A031576	DUKE UNIVERSITY	248445/A031576	\$1,698	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	KEMRI - SALMONELLA TYPHI	KENYA MEDICAL RSRCH INSTITUTE	KEMRI - SALMONELLA TYPHI	-\$2,598	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	KEMRI - SALMONELLA TYPHI	KENYA MEDICAL RSRCH INSTITUTE	KEMRI - SALMONELLA TYPHI	\$13,844	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	A538211	EMORY UNIVERSITY	A538211	\$17,700	\$9,008,759	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM113236-04			\$34,467	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-04			\$116,429	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-04			\$84,607	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-04			\$58,746	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1K08GM124499-01A1			-\$2,018	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K08GM124499-02			-\$2,191	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K08GM124499-03			\$142,026	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K08GM124499-04			\$34,115	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	7R35GM131875-04			\$40,320	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	430-40-18A	IOWA STATE UNIVERSITY	430-40-18A	\$169,216	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	4688187	INDIANA UNIVERSITY	4688187	\$71,546	\$747,263	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	9116-NCH	INDIANA UNIVERSITY	9116-NCH	\$12,758	\$5,808,148	N/A	\$0
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3UG1HD083170-05S1			-\$228	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD068278-10			\$79,031	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD068278-11			\$197,554	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R25HD086885-05			\$51,126	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD088033-04			\$35,482	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD088033-05			\$1,315	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5K01HD083459-05			\$48,050	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD081120			-\$14,653	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD081120-05			\$7,954	\$147,881	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD093706-03			\$196,085	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD091347-02			\$28,918	\$32,241	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD091347-03			\$777,359	\$961,639	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3R01HD091347-03S1				\$39,508	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD091347-04				\$46,534	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3R01HD091347-04S1				\$8,817	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD074594-07				\$129,007	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD074594-08				\$57,265	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5K99HD093814-02				\$111	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD098176-02			\$101,703	\$258,345	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD095976-02			\$131,346	\$251,972	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD095976-03			\$125,354	\$326,903	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R03HD099241-02			\$9,909	\$42,673	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	4R00HD096115-03				\$154,095	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R00HD096115-04				\$80,702	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R21HD099575-01A1			\$1,783	\$101,436	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R21HD099575-02			\$2,311	\$84,696	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD100493-01A1				\$203,457	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD100493-02				\$212,380	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD098175-01A1			\$240,579	\$332,209	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD098175-02				\$45,047	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD100420-01A1			\$107,993	\$270,509	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD100420-02				\$52,542	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R21HD106252-01				\$29,726	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R11HD107783-01				\$60,236	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60049375	THE OHIO STATE UNIVERSITY	60049375	\$3,205	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GR120740	THE OHIO STATE UNIVERSITY	GR120740	\$11,473	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60076109-NCH	OSU COLLEGE OF MEDICINE	60076109-NCH	\$30,304	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMCS3266	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMCS3266	-\$96	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	216392	RTI INTERNATIONAL	216392	\$255,089	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH	\$3,487	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108

CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH	\$5,331	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH	\$1,452	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH	\$9,933	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH	\$401	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3004685877	REGENTS UNIVERSITY OF MICHIGAN	3004685877	\$86,283	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60061164	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60061164	\$1	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60061164	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60061164	\$7,787	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GR101278 / SPC-1000003590	THE OHIO STATE UNIVERSITY MEDICAL CENTER	GR101278 / SPC-1000003590	\$15,754	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1644 G VA041	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	1644 G VA041	\$317	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60067323	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067323	\$4,879	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R70507-3213	EASTERN MICHIGAN UNIVERSITY	R70507-3213	\$13,167	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R70507-3213	EASTERN MICHIGAN UNIVERSITY	R70507-3213	\$18,644	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OSP2018144	UNIVERSITY OF MASS, WORCESTER	OSP2018144	\$39,677	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OSP2018144	UNIVERSITY OF MASS, WORCESTER	OSP2018144	\$40,170	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	30004942-09	CHILDREN'S NATIONAL MEDICAL CENTER	30004942-09	\$32,297	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	30004942-09	CHILDREN'S NATIONAL MEDICAL CENTER	30004942-09	\$36,584	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	NCH31227-01	LA BIOMEDICAL RESEARCH INST	NCH31227-01	\$103,339	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	17630	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS	17630	-\$5,573	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	FY20.812.008 / 2-5-A9096	UNIVERSITY OF COLORADO DENVER	FY20.812.008 / 2-5-A9096	\$4,822	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	FY20.812.008 / 2-5-A9096	UNIVERSITY OF COLORADO DENVER	FY20.812.008 / 2-5-A9096	\$7,041	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	412575-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412575-19D50	\$23,357	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	412575-19D50	VIRGINIA POLYTECHNIC INSTITUTE	412575-19D50	\$45,470	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60077380	THE OHIO STATE UNIVERSITY	60077380	\$26,090	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000004188 / GR119858	THE OHIO STATE UNIVERSITY	SPC-1000004188 / GR119858	\$44,214	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A21-0004-S002 - NCH	ANN & ROBERT H. LURIE CHILDREN'S	A21-0004-S002 - NCH	\$16,271	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	A21-0004-S002 - NCH	ANN & ROBERT H. LURIE CHILDREN'S	A21-0004-S002 - NCH	\$51,298	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60078268	THE OHIO STATE UNIVERSITY	60078268	\$29,480	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	SPC-1000004338 / GR120536	THE OHIO STATE UNIVERSITY	SPC-1000004338 / GR120536	\$25,192	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD091302	THE MEDICAL COLLEGE OF WI INC.	R01HD091302	\$21,454	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD091302	THE MEDICAL COLLEGE OF WI INC.	R01HD091302	\$22,068	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762	\$29,380	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762	\$6,044	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	GRT-00000762	THE CHILDREN'S HOSPITAL OF PA	GRT-00000762	\$21,924	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	304848	CHILDREN'S HOSPITAL MEDICAL CENTER	304848	\$373	\$5,808,148	RESEARCH AND DEVELOPMENT	\$71,513,108
AGING RESEARCH	93.866	SR01AG050581-05			\$54,832	\$184,588	RESEARCH AND DEVELOPMENT	\$71,513,108
AGING RESEARCH	93.866	60067217	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067217	\$3,963	\$184,588	RESEARCH AND DEVELOPMENT	\$71,513,108
AGING RESEARCH	93.866	60079573	THE OHIO STATE UNIVERSITY	60079573	\$27,551	\$184,588	RESEARCH AND DEVELOPMENT	\$71,513,108
AGING RESEARCH	93.866	000526371-SC002	BOARD OF TRUSTEES UNIV OF AL	000526371-SC002	\$90,587	\$184,588	RESEARCH AND DEVELOPMENT	\$71,513,108
AGING RESEARCH	93.866	GR122536 / R21AG071133	THE OHIO STATE UNIVERSITY	GR122536 / R21AG071133	\$7,655	\$184,588	RESEARCH AND DEVELOPMENT	\$71,513,108
VISION RESEARCH	93.867	SITE ID 26	JAEB CENTER FOR HEALTH CHILDREN'S HOSPITAL OF PHILADELPHIA	SITE ID 26	\$20,073	\$36,596	RESEARCH AND DEVELOPMENT	\$71,513,108
VISION RESEARCH	93.867	3209850817		3209850817	\$6,214	\$36,596	RESEARCH AND DEVELOPMENT	\$71,513,108
VISION RESEARCH	93.867	ROP2Y	JAEB CENTER FOR HEALTH		\$913	\$1,388	RESEARCH AND DEVELOPMENT	\$71,513,108
VISION RESEARCH	93.867	60058914	THE OHIO STATE UNIVERSITY	60058914	\$5,870	\$8,921	RESEARCH AND DEVELOPMENT	\$71,513,108

MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0420	OHIO DEPARTMENT OF HEALTH	02560511MH0420		-\$3,376	\$666,345	N/A	\$0
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0521	OHIO DEPARTMENT OF HEALTH	02560511MH0521		\$519,970	\$666,345	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0622	OHIO DEPARTMENT OF HEALTH	02560511MH0622		\$149,751	\$666,345	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	ASPR	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	ASPR		\$98,586	\$165,626	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	ASPR	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER	ASPR		\$31,796	\$165,626	RESEARCH AND DEVELOPMENT	\$71,513,108
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	47318	OHIO DEPARTMENT OF HEALTH	47318		\$35,244	\$165,626	RESEARCH AND DEVELOPMENT	\$71,513,108
RURAL HEALTH CARE SERVICES OUTREACH, RURAL HEALTH NETWORK DEVELOPMENT AND SMALL HEALTH CARE PROVIDER QUALITY IMPROVEMENT	93.912	HRSA-RCORP-NCH	HOPEWELL HEALTH CENTERS	HRSA-RCORP-NCH		\$11,512	\$11,512	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$52,398	\$423,720	RESEARCH AND DEVELOPMENT	\$71,513,108
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		-\$2,675	\$423,720	RESEARCH AND DEVELOPMENT	\$71,513,108
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$15,698	\$423,720	RESEARCH AND DEVELOPMENT	\$71,513,108
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$198,950	\$423,720	RESEARCH AND DEVELOPMENT	\$71,513,108
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$114,359	\$423,720	RESEARCH AND DEVELOPMENT	\$71,513,108
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	CPH RWPA	THE CITY OF COLUMBUS	CPH RWPA		\$44,990	\$423,720	RESEARCH AND DEVELOPMENT	\$71,513,108
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76HA247360900				\$223,873	\$566,494	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76HA24736-10-00				\$284,433	\$566,494	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	6 P06HA337580101				\$10,868	\$566,494	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	1 H7CHA37187-01-00				\$47,320	\$566,494	N/A	\$0
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	2100143 OMHAS	OHIO DEPARTMENT OF MENTAL HEALTH	2100143 OMHAS	\$52,293	\$52,293	\$67,387	RESEARCH AND DEVELOPMENT	\$71,513,108
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	2200026	OHIO DEPARTMENT OF MENTAL HEALTH	2200026	\$15,094	\$15,094	\$67,387	RESEARCH AND DEVELOPMENT	\$71,513,108
MONITORING JUVENILE ONSET RECU	93.RD	S270141-12	EASTERN VIRGINIA MEDICAL SCHOOL	S270141-12		\$0	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
WORKING CANINE GENETIC MAPPING	93.RD	US001-0000765771	BATTELLE MEMORIAL INSTITUTE	US001-0000765771	\$3,449	\$221,347	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
INFLUENZA VACCINE EFFECTIVENES	93.RD	1758484	BOSTON CHILDREN'S HOSPITAL	1758484		\$12,128	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BLGSP	93.RD	21X013F	LEIDOS BIOMEDICAL RESEARCH, INC	21X013F		\$49,356	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
MOUNT SINAI FLU STUDY	93.RD	0258-A504-4609	MOUNT SINAI SCHOOL OF MEDICINE	0258-A504-4609		\$67,298	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
HRSA IDIQ	93.RD	75R60221D00001			\$42,641	\$241,632	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
NEISS	93.RD	CPS-21131-21-0136				\$23,558	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
HRSA T05-TO SUPPORT THE ACHDNC	93.RD	A030564	DUKE UNIVERSITY	A030564		\$3,571	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
HRSA TASK ORDER 8	93.RD	A032743	DUKE UNIVERSITY	A032743		\$57,487	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
HRSA TASK ORDER 8	93.RD	A032743	DUKE UNIVERSITY	A032743		\$1	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
T06 HRSA	93.RD	A030693	DUKE UNIVERSITY	A030693		-\$9,498	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001				\$8	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001 P00006				-\$2,951	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001 P00006				-\$1	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001 P00008				\$1,286,416	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001 P00008				\$65,029	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001 P00010				\$573,074	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001 P00010				\$28,564	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
NCI BCR T0#2 OPTION A	93.RD	HHSN26100002				\$7,700	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
NCI BCR T0#2 BASE	93.RD	HHSN26100002				\$496,382	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
NCI BCR T0#2 CBA	93.RD	HHSN26100002				\$4,378	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
NCI BCR T0#2 INT SHIP	93.RD	HHSN26100002				\$4,834	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
19X092Q2-LEIDOS-PERLMAN STUDY	93.RD	19X092Q2	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q2		\$13,201	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
LBR 11XS089	93.RD	11XS089	LEIDOS BIOMEDICAL RESEARCH, INC	11XS089		-\$26,487	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
12XS383 HTMCP DATA COLLECTION	93.RD	12XS383	LEIDOS BIOMEDICAL RESEARCH, INC	12XS383		\$76,364	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
PEDIATRIC NCI - MATCH APEC1621	93.RD	17X033Q2	LEIDOS BIOMEDICAL RESEARCH, INC	17X033Q2		\$962,616	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
17X033 TO: Q3 BPU ETCN NCLN	93.RD	17X033	LEIDOS BIOMEDICAL RESEARCH, INC	17X033		\$460,150	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
19X092Q1-LEIDOS-LOH STUDY	93.RD	19X092Q1	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q1		\$408,369	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
19X092Q3 - LEIDOS - TEWARI	93.RD	19X092Q3 18X104	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q3 18X104		\$80,615	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
HTMCP NEW CYCLE	93.RD	21X148Q	LEIDOS BIOMEDICAL RESEARCH, INC	21X148Q		\$18,494	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
BPC EOMI T07	93.RD	HHSN2612017000151				\$3,036	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
NCI BCR TASK ORDER #3	93.RD	75N91021F000				\$11,466	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
T05: NUCLEIC ACID EXTRACTIONS	93.RD	HHSN2612017000151				-\$1,713	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
T06: NUCLEIC ACID EXTRACTIONS	93.RD	HHSN2612017000151				\$201,700	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108

A TARGETED APPROACH TO A SAFER	93.RD	RNG002833-BUDG03 SUB NCH MOD2	KFHPW FORMERLY GROUP HEALTH RI CHILDREN'S HOSPITAL OF PHILADELPHIA	RNG002833-BUDG03 SUB NCH MOD2	\$162,621	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
ADENOVIRUS STEM CELL	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621	\$6,098	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
ADENOVIRUS - OPTION 2	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621	\$36,356	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
ORAL VALGANCICLOVIR	93.RD	000509729-001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000509729-001	\$4,020	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
MATERNAL AND INFANT NETWORK	93.RD	60079138	THE OHIO STATE UNIVERSITY	60079138	\$18,278	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
OPNA EXPOSURE	93.RD	SPC-1000004616 / GR120172	THE OHIO STATE UNIVERSITY	SPC-1000004616 / GR120172	\$172,116	\$5,737,613	RESEARCH AND DEVELOPMENT	\$71,513,108
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$10,218,090	\$152,834,737		
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$11,045,765	\$157,558,755		

Please Note:

Italicized award lines indicate pass-through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to the Schedule of Expenditures of Federal Awards

December 31, 2021

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Nationwide Children's Hospital, Inc. and Subsidiaries under programs of the federal government for the year ended December 31, 2021. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Expenditures reported on the Schedule are reported on the accrual basis of accounting. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

2. 10% De Minimis Cost Rate

Nationwide Children's Hospital, Inc. and Subsidiaries did not use the de minimis cost rate.

3. COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution (Assistance Listing 93.498)

The Schedule includes \$81,583,962 received from the U.S. Department of Health and Human Services (HHS) under the Provider Relief Fund (PRF) program of Assistance Listing Number 93.498. In accordance with guidance from HHS, the Schedule includes all funds received between July 1, 2020 and December 31, 2020, and expended by December 31, 2021. Such amounts were recognized as other revenue in Nationwide Children's Hospital, Inc. and Subsidiaries' consolidated financial statements in the accompanying consolidated statements of operations and changes in net assets for the years ended December 31, 2021 and 2020. The amount included on the Schedule for the year ended December 31, 2021, includes the following providers and tax identification numbers (TINs):

Provider Name	TIN	PRF Amount
Nationwide Children's Hospital	314379441	\$ 74,078,965
Pediatric Academic Association, Inc.	311024403	5,480,622
Children's Anesthesia Associates, Inc.	310650338	2,024,375
Total		<u>\$ 81,583,962</u>

Internal Control and Compliance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Senior Management and the Board of Directors
Nationwide Children's Hospital, Inc. and Subsidiaries

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Nationwide Children's Hospital, Inc. and Subsidiaries, which comprise the consolidated balance sheet as of December 31, 2021, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated April 26, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control. Accordingly, we do not express an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Nationwide Children's Hospital, Inc. and Subsidiaries' financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst & Young LLP

April 26, 2022

Report of Independent Auditors on Compliance for the Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors
Nationwide Children's Hospital, Inc. and Subsidiaries

Report of Independent Auditors on Compliance for the Major Federal Program

Opinion on the Major Federal Program

We have audited Nationwide Children's Hospital, Inc. and Subsidiaries' compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on Nationwide Children's Hospital, Inc. and Subsidiaries' major federal program for the year ended December 31, 2021. Nationwide Children's Hospital, Inc. and Subsidiaries' major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, Nationwide Children's Hospital, Inc. and Subsidiaries complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended December 31, 2021.

Basis for Opinion on the Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Nationwide Children's Hospital, Inc. and Subsidiaries and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program. Our audit does not provide a legal determination of Nationwide Children's Hospital, Inc. and Subsidiaries' compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to Nationwide Children's Hospital, Inc. and Subsidiaries' federal program.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Nationwide Children's Hospital, Inc. and Subsidiaries' compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Nationwide Children's Hospital, Inc. and Subsidiaries' compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Nationwide Children's Hospital, Inc. and Subsidiaries' compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2021-001 related to COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution for Activities Allowed or Unallowed Costs. Our opinion on the major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on Nationwide Children's Hospital, Inc. and Subsidiaries' response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. Nationwide Children's Hospital, Inc. and Subsidiaries' response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify a deficiency in internal control over compliance that we consider to be a material weakness.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as item 2021-001 related to COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution for Activities Allowed or Unallowed Costs and Reporting to be a material weakness.

A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on Nationwide Children's Hospital, Inc. and Subsidiaries' response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. Nationwide Children's Hospital, Inc. and Subsidiaries' response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst & Young LLP

September 30, 2022

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs

Year Ended December 31, 2021

Section I – Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

_____ **Yes** X **No**

Significant deficiency(ies) identified?

_____ **Yes** X **None reported**

Noncompliance material to financial statements noted?

_____ **Yes** X **No**

Federal Awards

Internal control over major federal program:

Material weakness(es) identified?

 X **Yes** _____ **No**

Significant deficiency(ies) identified?

_____ **Yes** X **None reported**

Type of auditor's report issued on compliance for major federal program:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 X **Yes** _____ **No**

Identification of major federal program:

Assistance Listing Number	Name of Federal Program or Cluster
93.498	COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution

Dollar threshold used to distinguish between Type A and Type B programs:

\$ 3,000,000

Auditee qualified as low-risk auditee?

 X **Yes** _____ **No**

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

No matters were reported.

Section III – Federal Award Findings and Questioned Costs

Finding 2021-001

Information on the federal program:

Federal Program: COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Distribution

Federal Agency: U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

Assistance Listing: 93.498

Criteria or specific requirement (including statutory, regulatory, or other citation):

The Uniform Guidance 2 CFR Section 200.303 states, “The Non-Federal entity must:

Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Provider Relief Fund General and Targeted Distribution Post-Payment Notice of Reporting Requirements June 11, 2021 indicates that:

- Allowable equipment expenses include, “Expenses paid for purchase of equipment used for infection control, such as updates to HVAC systems or sanitizing equipment.”
- “The Reporting Entity will report on unreimbursed expenses attributable to coronavirus (net after other assistance received and PRF payments are applied).”
- “Expenses that are paid for with General and Targeted PRF payments must be those that are unreimbursed by other sources and that other sources are not eligible to reimburse.”

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

Management did not retain documentation over the review and approval of the PRF terms and conditions reporting (T&Cs).

Management did not retain documentation over its review and approval of the lost revenue calculation and the report submitted in the HHS HRSA portal.

Management did not retain supporting documentation over certain payroll expenses.

Total expenses reported in the HHS HRSA portal for period 1 and period 2 did not agree to the books and records of Nationwide.

Cause:

Management did not have suitably designed internal controls over the review and approval of the T&Cs, the lost revenue calculation, and HHS HRSA portal submission.

Management did not have internal controls in place to require supporting documentation of payroll expenses charged to the PRF program be retained.

Effect or potential effect:

The lack of documentation of the PRF T&Cs could result in Nationwide not being in compliance with the PRF T&Cs.

The lack of documentation of the review and approval of the lost revenue calculation and portal submission could result in error in the lost revenue calculation or report submitted to the HHS HRSA portal.

The lack of review and approval of expenses used for PRF reporting resulted in unallowable expenses being charged to the PRF program.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Questioned costs:

Assistance Listing No. 93.498, COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution – total questioned costs are \$64,171.

- \$6,741 relates to employees where supporting documentation for their PRF payroll was not available
- \$57,430 relates to expenses charged to the PRF program in excess of actual program expenses

Context:

We selected a sample of 40 payroll transactions totaling \$67,209 and noted three payroll selections totaling \$6,471 that management was unable to provide support that they were related to COVID-19. Total payroll expense was \$16,849,658.

Total PRF expenses reported in the portal for Periods 1 and 2 were \$3,635,748 and actual PRF expense were \$3,578,318; the difference of \$57,430 could not be supported.

Nationwide reported expense in period 1 of \$19,233,526, while actual expenses were \$18,916,134. NCH report expenses in Period 2 of \$1,997,042 while actual expenses were \$3,635,748. We noted that \$809,301 of the difference represented an understatement of expenses in Period 1 and an overstatement of expenses in Period 2 for the same amount. The remaining difference of \$57,430 is described in the above paragraph.

Total PRF lost revenue and expenditures reported on the schedule of federal awards are \$81,583,962 for the year ended December 31, 2021.

Identification as a repeat finding, if applicable:

This is not a repeat finding.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Recommendation:

Management should reassess its internal controls over the review and approval of the allowability of expenditures, the lost revenue calculation, and reporting in the HRSA portal.

Views of responsible officials:

Management’s corrective action plan includes:

- Document the review of the PRF terms and conditions and HHS filing by the CFO.
- Ensure that documentation related to expenses included in the HHS filing is complete and reconciles to the books and records of Nationwide Children’s Hospital.
- Incorporate any expenses reported in error into the 2023 HHS filing for PRF funds received in 2022.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2022 Ernst & Young LLP.
All Rights Reserved.

ey.com



**Management's Corrective Action Plan
For the Year Ended December 31, 2021**

Finding 2021-001 – COVID-19 Provider Relief Fund (PRF)

Grantor:	U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)
Federal Program:	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
Assistance Listing #:	93.498
Title:	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
Award Year:	Fiscal year 2021 1/1/2021 – 12/31/2021
Award Number:	None listed

Management agrees with the recommendation. Management will implement the recommendations in its reporting of funds received under the Provider Relief Fund for 2022 and any subsequent fiscal years as applicable.

Corrective Action Plan and Anticipate Completion Date

Management's corrective action plan includes:

- Document the review of the PRF terms and conditions and HHS filing by the CFO.
- Ensure that documentation related to expenses included in the HHS filing is complete and reconciles to the books and records of Nationwide Children's Hospital.
- Incorporate any expenses reported in error into the 2023 HHS filing for PRF funds received in 2022.

Responsible Person: Mary Beth Colatruglio, CPA – Director of Accounting

Effective Date: December 31, 2022